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Almost all vascular diseases are linked to an inflammatory milieu that produces a 
toxic brew of angiogenic and inflammatory cytokines, which distort tissue architecture 
and function.  These cytokines are produced by a cohort of cells, including endothelial 
cells, which line blood vessels, and immune cells such as platelets, which are derived 
from megakaryocytes. Under nonpathological conditions, these cells help to maintain 
vessel integrity, but when activated by disease states they release cytokines to cause 
immediate, direct, and disruptive effects on the vascular barrier. 
In this dissertation I present the results of studies that examine the molecular 
signaling required to produce one of these immune cells, the platelet, during vessel 
maintenance as well as examination of the pathological contribution of cytokines on 
another immune cell, the endothelial cell. I show that under nonpathological conditions, 
platelets are required for vessel homeostasis, and it is through inhibition of RhoA 
signaling by proteasomal degradation that platelets are formed.  Under pathological 
conditions, I demonstrate that pro-inflammatory and proangiogenic cytokines signal 
through a small GTPase, ARF6, in endothelial cells, and that ARF6 is the proximal 
convergence point regulating downstream signaling leading to endothelial barrier 
disruption and vessel permeability. This reveals ARF6 as a therapeutic target in vascular 
diseases such as arthritis and diabetic retinopathy. These studies fundamentally inform a
iv 
mechanism for the genesis of platelets in maintenance of normal barrier function and 
establish a therapeutic target when vessel homeostasis is disrupted in endothelial cells. 
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This thesis is divided into two parts and because of that, I will be presenting two 
introductions to the give the reader a better understanding of the background and basis for 
my research. In this chapter, I will first go over some megakaryocyte and platelet 
biology. Then I will cover some insights on receptor endocytosis and signal amplification 
in VEGF signaling.  
 
Introduction to Multiple Myeloma and Megakaryocyte Biology 
Multiple myeloma is a cancer of the plasma cells in the bone marrow. Affecting 1 
in 100,000 people per year, multiple myeloma can lead to renal failure, anemia, and bone 
damage1,2. Proteasome inhibition has become a first line treatment against multiple 
myeloma with drugs such as bortezomib inhibiting the proteasome to disrupt NF-κB 
signaling, leading to cancer cell death3,4. However, a dose limiting side-effect of 
proteasome inhibition is thrombocytopenia5,6. This suggests that a further understanding 
of the role of the proteasome in thrombopoiesis may lead to more efficient and less toxic 
treatment regimens for patients.  
The primary role of megakaryocytes is to make platelets by extending long, 
branching, cytoplasmic processes, called proplatelets, into blood vessels7,8. Platelets aid 
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in hemostasis and contribute to the formation of blood clots7. While the mechanism of 
platelet production and destruction has been studied, very little is known about what 
initiates and regulates these processes8. Proteasome inhibitors like bortezomib can induce 
thrombocytopenia via two mechanisms: either through a decrease in platelet production 
or an increase in platelet destruction9. Since multiple myeloma patients on bortezomib 
experience a refractory spike in platelet counts when the drug is terminated, we 
hypothesized that bortezomib induces a decrease in platelet production because recovery 
from platelet destruction is more gradual3.  
Mechanistically, it is clear that proteasome inhibition prevents the degradation of 
IκB, a protein complex that holds NF-κB in the cytoplasm of cells10. This prevents the 
translocation of NF-κB into the cell nucleus and the activation of downstream 
transcription factors. In multiple myeloma, there is over-activation of NF-κB signaling 
and it has been show that a reduction of NF-κB signaling causes apoptosis. This is why 
proteasome inhibition is beneficial in multiple myeloma because it kills cancer cells by 
inhibiting degradation of IκB and thus, release and translocation of NF-κB into the 
nucleus11. It is also thought that bortezomib-induced thrombocytopenia is a side-effect of 
of NF-κB signaling inhibition12. However, there is no evidence supporting this 
hypothesis. Thus, we wished to delineate whether NF-κB signaling is involved in 
bortezomib-induced thrombocytopenia. 
Since the proteasome is known to degrade numerous proteins, it is likely that NF-
κB signaling may not be involved in thrombopoiesis at all. Very little is actually known 
about the specific functions of the proteasome pathway in megakaryocytes and platelets, 
but even if NF-κB signaling is not involved in bortezomib-induced thrombocytopenia, we 
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hoped to learn something new about thrombopoiesis by screening for other proteins that 
are regulated by the proteasome in megakaryocytes. These include pro-alphaIIbeta 
integrin and the thrombopoietin receptor c-Mpl, which have both been associated with 
thromobopoiesis in the literature and can be degraded by the proteasome13,14. 
In conjunction with our studies in vitro, we developed two megakaryocyte- 
specific Psmc1 conditional knockout mice. Psmc1 is necessary for 26S proteasome 
function and has been used to study the role of the proteasome in neurons15. We mated 
the Psmc1 (floxed/floxed) mice with two megakarocyte cre drivers, an inducible Pdgf-cre 
and a noninducible Pf4-cre. Using these mice, we aimed to test the hypothesis that lack 
of proteasome function is sufficient to disrupt proplatelet formation. The results of our 
findings make up the next chapter of this thesis. 
 
Introduction to VEGF and Receptor Tyrosine Kinase Signaling 
The second part of my thesis (Chapters 3 and 4) focuses on endothelial cells, 
which line the blood vessel, and regulate the exchange between intravascular and 
extravascular compartments. Endothelial cells use tight cell-cell junctions made up of 
cadherins and catenins to maintain vascular stability and to limit vascular leak. In 
neovascular and inflammatory diseases like sepsis, influenza, and diabetic retinopathy, 
the endothelium is destabilized by proinflammatory and/or proangiogenic cues such as 
interleukin-1beta and vascular endothelial growth factor (VEGF) which signals for 
cadherin and catenin internalization.  
VEGF is essential to the development and maintenance of the vascular 
endothelium16. VEGF binding to its receptor, Vascular Endothelial Growth Factor 
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Receptor 2 (VEGFR2), promotes endothelial cell growth and migration, which drives 
vessel development17. VEGFR2 is a receptor tyrosine kinase (RTK) that, upon ligand 
binding, dimerizes, trans-phosphorylates multiple intracellular residues18, and triggers 
several downstream pathways including PKC-MARCKS and Raf1-MEK1-ERK 17,19,20.  
Signal transduction by VEGFR and other RTKs is highly dependent on receptor 
internalization and intracellular trafficking, first elucidated to explain how the sis 
oncogene, encoding platelet-derived growth factor, transformed cells whilst continuous 
extracellular exposure of growth factors did not 21. This understanding of internalization 
and trafficking as a component of growth factor signaling applied not only in patho-
physiogical signaling seen in oncogenesis, but also in physiological signaling mediated 
by RTKs.  
RTK signaling is complex, but here, I would like to give a brief overview of the 
nuances in signaling. Like most proteins, RTKs are synthesized in the endoplasmic 
reticulum, transported to the Golgi, and then delivered to the plasma membrane. Under 
homeostatic conditions, RTKs undergo a basal rate of endocytosis and recycling. The rate 
of constitutive internalization and recycling varies and is both receptor and cell type 
dependent. For example, for EGFR in carcinoma cells, turnover can take 24 hours while 
for VEGFR in retinal endothelial cells, turnover is typically less then 1 hour22.  
Ligand binding activates RTKs and eventually leads to the down-regulation of the 
receptor. It is well know that RTKs are activated by receptor dimerization, trans 
phosphorylation of multiple intracellular sites, and subsequent signaling to various 
pathways with the help of adaptor proteins which bind to phosphorylated RTKS as 
illustrated above in VEGF signaling. However, whether this signaling occurs at the cell 
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surface or inside the cell is debatable23,24. For instance, a pool of RTKs can be held 
immobile at the cell membrane inside microvilli or caveolae25. In EGFR signaling, such a 
pool can still signal but activation is dampened26. It is unclear whether this affect is true 
of all arms of EGFR signaling but this does suggests that internalization is involved in 
signaling amplification. 
The historic view of RTK endocytosis is that it leads to signal attenuation. 
Though this is eventually true, a more nuanced understanding of receptor endocytosis has 
developed in the last decade. Internalized RTKs can activate pathways from endosomes, 
suggesting distinct signaling pathways exist that require RTK endocytosis23.  This 
internalization may or may not be clathrin dependent but it seems that temporal and 
spatial relationships are key for signal amplification27,28.  This could be because 
endosomes proved an attractive environment for facilitating protein-protein interactions 
and maintenance of signal complexes. This could also be because endosomes travel and 
can bring together the right adaptor proteins with the activated RTK. Either way, the 
kinetics and final destination of the RTK seem to be tightly regulated29. 
Besides amplifying signals, internalization of RTKs can lead to signal attenuation. 
For example, phosphatases on the endoplasmic reticulum can dephosphorylate and 
inactivate RTKs in late endosome compartments30. To focus more on VEGF signaling 
and specifically VEGFR2 (since not much is known about endocytosis of VEGFR1 and 
VEGFR3), I want to highlight that VEGF internalization can also lead to receptor 
dephosphorylation17. Yet, like with other RTKs, endocytosis of VEGFR2 seems to 
increase signaling too. 
It is thought that a protein complex composed of ephrin-B2 (a co-receptor for 
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VEGFR2), Dab2, and Par-3 associates with activated VEGFR2 in clathrin-coated vesicles 
and that the formation of this complex signals for trafficking of the receptor to the early 
endosome (marked by Rab5). In the early endosome, VEGFR2 can signal to ERK1/2 and 
RAC1 which can be blocked by inhibiting trafficking of VEGFR231. It is unknown what 
other proteins may be involved in this early trafficking step or how signaling is amplified 
later now. Thus, though we know endocytosis can increase signaling, the precise 
mechanism and details remain obscure.  
Since we are interested in signal amplification, it came to our attention that 
receptor-coreceptor binding could regulate the strength of extracellular VEGF signals as 
well. For instance, knockdown of ephrinB2 decreases the level of VEGF-induced 
VEGFR2 phosphoralation at the 1175 site. This seems to also affect receptor endocytosis 
though it is unclear whether a decrease in phosphorylated VEGFR2 precedes this 
process32,33.  
More recent studies have highlighted the interaction between VEGFR2 and 
another co-receptor called Neuropilin 1 (NRP1)34-36. NRP1 is a 130-140 kDa 
glycoprotein that was first identified in the nervous system37. It is highly conserved and 
in the nervous system, it is localized on neurons to guide axon formation. In the vascular 
system NRP1 is expressed on small and large vessels but is not ubiquitous38. For 
example, NRP1 seems to be more common in blood islands, which are early vascular 
structures, and in arterioles39. Knockout of the cytoplasmic domain of NRP1 impairs 
VEGFR2, phosphorylation and VEGFR2/NRP1 complexes formed in trans inhibit the 
amount of VEGFR2 internalized40,41. NRP1 seems to be essential for vascular 
morphogenesis but how it guides vascular development is still not completely 
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understood.  
Trafficking of proteins from the plasma membrane and within intracellular 
compartments is dominated by small GTPases, especially those of the Ras superfamily 
such as Rab and Arf42,43. These molecules are GDP/GTP binding proteins that are active 
when bound to GTP and inactive when bound to GDP. Studies in Saccharomyces 
cerevisiae have shown that sequential steps in trafficking, from the endoplasmic 
reticulum to the golgi to the plasma membrane are mediated by subfamilies of Rab 
proteins44,45. Our own work has defined a role for Arf6 in regulating trafficking of 
cadherins and catenins to and from the cell surface46,47. These insights led us to question 
whether Arf6 may be the critical player by which VEGFR2 controls its own receptor-
coreceptor internalization and signal amplification. 
Pharmaceutical targeting of RTKs has changed the landscape of cancer research48. 
Drugs like erlotinib and lapatinib are used to treat breast cancers by inhibiting epidermal 
growth factors receptors while bevacizumab and sunitinib are used to treat colon cancer 
by inhibiting VEGF-mediated signaling49,50. The discovery that VEGF levels are elevated 
in vascular eye diseases has also informed the use of anti-VEGF agents in a subset of eye 
diseases including age-related macular degeneration and diabetic retinopathy. So far, 
these anti-VEGF drugs focus on blocking ligand and receptor interactions at the cell 
surface (bevacizumab) or to poisoning RTK activity (sunitinib)51. Our elucidation of a 
mechanism by which VEGF regulates its receptor and co-receptor internalization to 
amplify signaling has the potential to build on this by offering a new strategy for 
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Introduction
Thrombocytopenia (low platelet count) is observed in numerous 
diseases and can be life threatening due to bleeding complica-
tions. Bortezomib, a reversible chemotherapeutic inhibitor used 
to treat patients with relapsed multiple myeloma, often induces 
thrombocytopenia within a few days of therapy initiation (1–3). 
Bortezomib-induced thrombocytopenia is dose-limiting, and if 
severe, bortezomib is withheld (2, 3). Although the mechanisms 
by which bortezomib induces thrombocytopenia is not clear, its 
primary mode of action is inhibition of the proteasome. The clini-
cal observation that platelet counts rise above pretherapy levels 
upon cessation of bortezomib treatment suggests that bortezomib 
affects thrombopoiesis (1, 3).
Like other cells, megakaryocytes and anucleate platelets pos-
sess proteasome activity (4, 5). While the specific functions of the 
proteasome in platelet precursors (e.g., megakaryocytes) is rela-
tively unknown (6), there is evidence that bortezomib alters the 
function of platelets (7–11). It has also been hypothesized, but not 
proven, that bortezomib inhibits megakaryocyte development via 
nuclear factor țB (NF-țB) (12). The aim of the present work was 
to precisely define the roles of the proteasome in thrombopoi-
esis and, in doing so, determine whether bortezomib-induced 
thrombocytopenia can be reversed. Using a combination of phar-
macologic and genetic tools, we showed that inhibition of protea-
some activity in megakaryocytes blocks proplatelet formation. In 
addition, conditional deletion of proteasome activity in mouse 
megakaryocytes led to severe thrombocytopenia and postnatal 
death. Decreased thrombopoiesis in proteasome-inhibited mice 
was caused by accumulation and increased activity of RhoA, and 
inhibitors of the RhoA signaling pathway restored platelet produc-
tion. These findings demonstrated that the megakaryocyte pro-
teasome controls the final stages of platelet production and also 
provided a potential option for restoring platelet counts in throm-
bocytopenic patients treated with bortezomib.
Results
Pharmacologic inhibition of the proteasome blocks platelet production. 
Due to its thrombocytopenic side effects, bortezomib is typically 
administered as a bolus twice weekly for 2 weeks (days 1, 4, 8, and 
11), followed by a 10-day rest period (3). To ascertain the immedi-
ate effects of this inhibitor on platelets, mice were administered 
a clinically relevant dose (2 mg/kg body weight) of bortezomib, 
and platelet counts and proteasome activity were measured. Con-
sistent with its well-known effect on platelet counts in patients, 
bortezomib induced a mild thrombocytopenia within 24 hours of 
The proteasome inhibiter bortezomib has been successfully used to treat patients with relapsed multiple myeloma; however, 
many of these patients become thrombocytopenic, and it is not clear how the proteasome influences platelet production. 
Here we determined that pharmacologic inhibition of proteasome activity blocks proplatelet formation in human and mouse 
megakaryocytes. We also found that megakaryocytes isolated from mice deficient for PSMC1, an essential subunit of the 26S 
proteasome, fail to produce proplatelets. Consistent with decreased proplatelet formation, mice lacking PSMC1 in platelets 
(Psmc1fl/fl Pf4-Cre mice) exhibited severe thrombocytopenia and died shortly after birth. The failure to produce proplatelets 
in proteasome-inhibited megakaryocytes was due to upregulation and hyperactivation of the small GTPase, RhoA, rather 
than NF-țB, as has been previously suggested. Inhibition of RhoA or its downstream target, Rho-associated protein 
kinase (ROCK), restored megakaryocyte proplatelet formation in the setting of proteasome inhibition in vitro. Similarly, 
fasudil, a ROCK inhibitor used clinically to treat cerebral vasospasm, restored platelet counts in adult mice that were made 
thrombocytopenic by tamoxifen-induced suppression of proteasome activity in megakaryocytes and platelets (Psmc1fl/fl Pdgf-
Cre-ER mice). These results indicate that proteasome function is critical for thrombopoiesis, and suggest inhibition of RhoA 
signaling as a potential strategy to treat thrombocytopenia in bortezomib-treated multiple myeloma patients.
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proplatelet formation in murine megakaryocytes. Bortezomib sig-
nificantly decreased proplatelet formation in fetal liver–derived 
megakaryocytes (Figure 2A). Similar responses were observed 
in human megakaryocytes, and removal of bortezomib from the 
incubation media restored proplatelet formation (Figure 2B and 
data not shown). To confirm that this effect was specific to pro-
teasome inhibition, megakaryocytes were treated with MG132 or 
lactacystin. Both proteasome inhibitors phenocopied the effects 
of bortezomib (Supplemental Figure 4 and data not shown). 
The inability to form proplatelets was accompanied by a notable 
increase in cell spreading on immobilized fibrinogen (Figure 2B), 
which indicates that the proteasome regulates key cytoskeletal 
proteins in megakaryocytes.
Phenotypic consequences of proteasome inhibition are independent 
of NF-țB and integrin ĮIIb. Bortezomib’s antitumor activity in mul-
tiple myeloma has been attributed to inhibition of NF-țB in plasma 
cells (14). Therefore, others have speculated that proteasome inhibi-
tors may induce thrombocytopenia via the NF-țB signaling path-
way (12). To test this hypothesis, we first treated megakaryocytes 
with bortezomib and examined the expression of nuclear factor of ț 
light polypeptide gene enhancer in B cells inhibitor, Į (IțBĮ), which 
sequesters NF-țB in the cytoplasm until it is phosphorylated, ubiqui-
tinated, and degraded (15). As expected, bortezomib increased the 
expression of IțBĮ in megakaryocytes (Figure 3A), which demon-
strated that inhibition of the proteasome blocks the NF-țB signaling 
pathway. We also found that inhibition of IțB kinase with SC-514, 
which induces IțBĮ phosphorylation, increased IțBĮ protein lev-
els in megakaryocytes (Figure 3A). However, unlike bortezomib, 
SC-514 did not halt proplatelet production (Figure 3B).
In addition to regulating NF-țB activity, Mitchell and col-
leagues previously demonstrated that the proteasome is capable of 
degrading pro–integrin ĮIIb (5). Based on this published work, and 
our present finding that inhibition of the proteasome decreased 
treatment (Figure 1A). The thrombocytopenia was transient and 
temporally correlated with inhibition of proteasome activity in cir-
culating platelets (Figure 1A).
To assess whether bortezomib-induced thrombocytopenia was 
due to accelerated clearance, we injected Dylight 488 conjugated to 
GPIBȕ into the bloodstream to track the lifespan of platelets in vivo 
in the presence of bortezomib or its vehicle. As expected, the num-
ber of labeled platelets decreased over 96 hours as platelets were 
cleared from the circulation (13). However, the number of labeled 
platelets was similar between bortezomib and vehicle treatment 
groups at every time point tested (Figure 1B). This suggested that 
bortezomib did not induce platelet activation in the bloodstream, 
which would facilitate platelet clearance. Consistent with this 
notion, we found that bortezomib did not directly induce activa-
tion of integrin ĮIIbȕ3 (Supplemental Figure 1; supplemental materi-
al available online with this article; doi:10.1172/JCI75247DS1), nor 
did it alter agonist-induced activation of integrin ĮIIbȕ3 or surface 
expression of P-selectin in mouse platelets (Supplemental Figures 
1 and 2). Similarly, bortezomib did not influence PAC-1 binding to 
human platelets in the presence or absence of agonist stimulation 
(Supplemental Figure 3 and data not shown).
Since acute administration of bortezomib did not shorten the 
lifespan of circulating platelets, we hypothesized that the bortezo-
mib-induced thrombocytopenia was due to a decrease in platelet 
production. To test this, we depleted platelets with an antibody 
against GPIBĮ and then treated mice with bortezomib or its vehi-
cle to determine whether bortezomib prevented platelet counts 
from rebounding. Platelet counts rebounded at a slower pace with 
bortezomib treatment than with the vehicle control (Figure 1C).
The data in Figure 1 suggested that bortezomib-induced 
thrombocytopenia was due to a defect in the formation of platelets 
from megakaryocytes. To examine this further, we determined 
whether inhibition of the proteasome with bortezomib blocked 
Figure 1. Pharmacologic inhibition of the 
proteasome induces thrombocytopenia in 
mice by decreasing platelet production. (A) 
Mice were treated with a bolus of bortezomib 
(Bort) or vehicle (Veh), and platelet counts and 
platelet proteasome activity were measured at 
the indicated times. Data are mean ± SEM of 6 
experiments. (B) Mouse platelets were labeled in 
vivo with Dylight 488, as described in Methods. 
In parallel, the mice were treated with a bolus 
of bortezomib or vehicle, and the percentage of 
labeled platelets was determined at 24, 48, and 
96 hours after treatment. Data are mean ± SEM of 
6 independent experiments. (C) Mouse platelets 
were depleted in the presence of bortezomib or its 
vehicle, as described in Methods. The percentage 
of platelets relative to baseline control (0 hours) 
is shown. Data are mean ± SEM of 5 independent 
experiments. Note that A–C are derived from 
separate experiments. *P < 0.05 vs. vehicle;  
#P < 0.05 vs. 0 hours.
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tory particle that is critical for ubiquitin-mediated protein degrada-
tion by the 26S proteasome complex (20–22). It is conserved at the 
protein level in human and mouse megakaryocytes (Supplemental 
Figure 8). mRNA for Psmc1 was also expressed in both species, 
although human megakaryocytes had lower levels of the transcript 
compared with mouse megakaryocytes (Supplemental Table 1).
Psmc1fl/fl mice were crossed with platelet factor 4 Cre recombi-
nase (Pf4-Cre) mice to disrupt proteasome activity in megakaryo-
cytes and platelets. Psmc1fl/fl Pf4-Cre mice had significantly reduced 
protein for PSMC1 in megakaryocytes, but not other tissues (Supple-
mental Figure 9). Ubiquinated proteins also accumulated in mega-
karyocytes from Psmc1fl/fl Pf4-Cre mice (Supplemental Figure 10).
Despite a marked reduction in PSMC1 protein, the number 
of megakaryocytes from Psmc1fl/fl Pf4-Cre mice in bone marrow or 
spleen was not reduced compared with Psmc1fl/wt mice (Supplemen-
tal Figure 11). Unlike their littermate controls, however, Psmc1fl/fl 
Pf4-Cre mice had severe thrombocytopenia at postnatal day 1 (P1), 
and the majority of Psmc1fl/fl Pf4-Cre mice died before weaning (Fig-
ure 5, A and B). The reduction in platelet counts was more severe 
than in c-Mpl knockout pups at the same age (Supplemental Figure 
12). In addition to reduced numbers of platelets, Psmc1fl/fl Pf4-Cre 
mice had lower hematocrits than Psmc1fl/wt mice, and bleeding was 
seen in the abdomen and limbs (Figure 5, C and D). Pathological 
signs of hemorrhage were also present in the bladder and testes of 
all animals and occasionally observed in the brain, lymph nodes, 
and intestines (Figure 5E and data not shown).
Ultrastructure examination of megakaryocytes from Psmc1fl/fl 
Pf4-Cre mice revealed less cytoplasm compared with megakaryo-
cytes from Psmc1fl/wt mice (Figure 6A). In addition, Psmc1fl/fl Pf4-
Cre megakaryocytes lacked demarcation membranes, which were 
readily visible in Psmc1fl/wt megakaryocytes (Figure 6A). Similar 
to mouse megakaryocytes treated with bortezomib (Figure 2A), 
megakaryocytes from Psmc1fl/fl Pf4-Cre mice failed to produce pro-
platelets (Figure 6B).
Inhibition of RhoA-dependent signaling prevents thrombocytopenia 
induced by genetic disruption of proteasome activity. As predicted from 
the pharmacological data, megakaryocytes from Psmc1fl/fl Pf4-Cre 
mice expressed higher levels of total RhoA protein and RhoA-GTP 
the formation of proplatelets when megakaryocytes adhere to 
fibrinogen, we sought to determine whether bortezomib regulated 
the activity of integrin ĮIIbȕ3 in megakaryocytes. Bortezomib did 
not alter the expression of mature integrin ĮIIb protein, nor did it 
increase binding of soluble fibrinogen or PAC-1 to human mega-
karyocytes (Supplemental Figure 5 and data not shown). Bortezo-
mib also had no effect on adherence of human megakaryocytes to 
fibrinogen (Supplemental Figure 6). Together, these data indicate 
that bortezomib does not directly block proplatelet formation 
through NF-țB– or integrin ĮIIbȕ3–dependent mechanisms.
Phenotypic consequences of proteasome inhibition require RhoA. 
The changes in actin polymerization observed in megakaryocytes 
treated with proteasome inhibitors were reminiscent of cytoskel-
etal changes in endothelial cells that rely on the small GTPase 
RhoA (16). Indeed, we found that bortezomib increased total 
RhoA protein expression (Figure 4A). Bortezomib also increased 
RhoA-GTP activity and phosphorylation of myosin light chain 
(MLC) kinase, which is downstream of RhoA (Figure 4, A and B).
RhoA-dependent signaling has been linked to the production 
of proplatelets (17, 18). Therefore, we treated human megakaryo-
cytes with Y27632, a selective inhibitor of the Rho-associated 
protein kinase p160ROCK, or with C3 transferase, a direct RhoA 
inhibitor. Y27632 and C3 transferase rescued proplatelet forma-
tion in bortezomib-treated cells (Figure 4C and Supplemental Fig-
ure 7). This response was likely due to inhibition of downstream 
RhoA effectors, because Y27632 decreased phosphorylation of 
MLC kinase in the presence of bortezomib (Figure 4B). In agree-
ment with the rescue of proplatelet formation observed in bort-
ezomib-treated human megakaryocytes, mouse megakaryocytes 
treated with bortezomib plus Y27632 or with bortezomib plus 
fasudil, a more clinically relevant p160ROCK inhibitor, formed 
proplatelets (Figure 4D). These results in mouse megakaryocytes 
were similar to a recent report by Murai et al. (19).
Genetic deletion of the proteasome results in severe thrombocyto-
penia and death. To further dissect the role of the proteasome in 
thrombopoiesis, we focused on protease (prosome, macropain) 
26S subunit, ATPase 1 (Psmc1; gene ID 19179) in mouse megakary-
ocytes and platelets. Psmc1 is an essential subunit of the 19S regula-
Figure 2. Pharmacologic inhibition of the proteasome blocks pro-
platelet formation in murine and human megakaryocytes. Mouse 
fetal liver–derived megakaryocytes (A) and human megakaryocytes 
(B) were pretreated with vehicle or bortezomib, and megakaryocytes 
producing proplatelets (PP) were examined. Shown are (A) represen-
tative transmission images and (B) representative confocal images 
with wheat germ agglutinin (WGA; red) and phalloidin (green) stain-
ing. Arrows denote proplatelet extensions. Also shown for each is the 
number of proplatelet-producing megakaryocytes relative to vehicle 
control. Data are mean ± SEM of 3 independent experiments.  
*P < 0.05 vs. vehicle. Scale bars: 100 ȝm (A); 50 ȝm (B).
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Our findings provide definitive proof that the megakaryocyte 
proteasome is required for the final stages of platelet production. 
Evidence for this is 2-fold: first, pharmacologic inhibition of pro-
teasome activity in late-stage human or mouse megakaryocytes 
significantly blunted proplatelet formation; and second, platelet 
production was significantly reduced in Psmc1fl/fl Pf4-Cre mice, in 
which genetic deletion of Psmc1 does not occur until megakaryo-
cytes express platelet factor 4, which activates the Cre recombi-
nase (23). In addition to regulating thrombopoiesis, others have 
shown that the proteasome is important for the proliferation of 
megakaryocyte precursors (24) and the degradation of cyclin B 
and pro–integrin ĮIIb in megakaryocytes (5, 25).
Like their parent megakaryocytes, anucleate platelets also 
possess proteasome activity (4, 10), and several groups have 
demonstrated that pharmacologic inhibition of the proteasome 
regulates platelet function (8–11, 26). Under the conditions of our 
experiments, bortezomib did not affect indices of platelet activa-
tion in mouse or human platelets that included activation of integ-
rin ĮIIbȕ3 and translocation of P-selectin to the surface of platelets. 
However, similar to Gupta and coworkers (8), we observed that 
bortezomib reduced the aggregation of human platelets when low 
concentrations of thrombin were used as the agonist (Supplemen-
tal Figure 14). Although more work is needed, results generated by 
multiple independent groups strongly indicate that protein degra-
dation systems regulate platelet function (6).
Other groups have shown that pharmacologic inhibition regu-
lates the function of platelets ex vivo (8–11, 26), but bortezomib 
did not accelerate the clearance of labeled platelets under the 
conditions of our present studies. Our results contrasted those of 
Nayak and colleagues (7), who showed that pharmacologic inhibi-
tion of the proteasome reduced the half-life of platelets in mice. 
One potential explanation for these discordant findings is that the 
bolus dose of bortezomib used in our studies only produced a mild 
thrombocytopenia and did not completely abolish platelet protea-
some activity (Figure 1A). Although Nayak’s group did not measure 
cellular proteasome activity (7), it is possible that they achieved 
more efficient pharmacologic inhibition of the proteasome in plate-
lets and other vascular cells. Different routes of drug administra-
Figure 3. Proteasome-dependent forma-
tion of proplatelets in human megakaryo-
cytes occurs independently of NF-țB.  
(A) Human megakaryocytes were treated 
with vehicle, bortezomib, or the NF-țB 
inhibitor SC-514. Shown are a represen-
tative Western blot for IțBĮ as well as 
IțBĮ expression levels, as measured by 
densitometry, relative to vehicle control. 
Data are mean ± SEM (n = 3). (B) Morphol-
ogy of megakaryocytes treated with vehicle, 
bortezomib, or SC-514. Megakaryocytes were 
stained with WGA (red), phalloidin (green), 
and DAPI (blue). Arrows denote proplatelets. 
Images are representative of 3 independent 
experiments. Also shown is the number of 
proplatelet-producing megakaryocytes rela-
tive to vehicle control. Data are mean ± SEM 
of 3 independent experiments. Scale bars:  
25 ȝm. *P < 0.05 vs. vehicle.
(Figure 7A). Fasudil also rescued proplatelet formation in bone mar-
row–derived megakaryocytes from Psmc1fl/fl Pf4-Cre mice (Figure 7B).
Next we generated inducible conditional knockouts by cross-
ing Psmc1fl/fl mice with platelet-derived growth factor–Cre estrogen 
receptor (Pdgf-Cre-ER) mice, which allowed for time-restricted dele-
tion of Psmc1 in megakaryocytes and platelets after administration of 
the competitive estrogen receptor ligand tamoxifen. Although Pdgf is 
expressed by other cells besides megakaryocytes, Pdgf-Cre-ER mice 
were used because Pf4-Cre-ER mouse lines are not currently avail-
able. Like Psmc1fl/fl Pf4-Cre mice (Figure 5, A and B), administration 
of tamoxifen to Psmc1fl/fl Pdgf-Cre-ER mice at P1 resulted in throm-
bocytopenia and early postnatal mortality (Supplemental Figure 13, 
A and B). When tamoxifen was administered to adult Psmc1fl/fl Pdgf-
Cre-ER mice, platelet counts were reduced by approximately 50% 
after 6 days compared with Psmc1fl/wt mice (Figure 8A). In the pres-
ence of fasudil, however, tamoxifen did not significantly decrease 
platelet counts in Psmc1fl/fl Pdgf-Cre-ER mice (Figure 8A). Consistent 
with these rescue experiments, staining of megakaryocytes in crude 
bone marrow showed that the in vivo fasudil treatment rescued pro-
platelet formation (Figure 8B). These results are consistent with our 
in vitro findings that fasudil maintained proplatelet formation in 
bortezomib-treated megakaryocytes (Figure 4D).
Discussion
In this study, we found that pharmacologic or genetic disruption of 
proteasome activity in megakaryocytes inhibits proplatelet forma-
tion. Pharmacologic inhibition was reversible in megakaryocytes 
treated in vitro with bortezomib, and thrombocytopenia was tran-
sient when bortezomib was administered as a bolus in vivo. When 
inhibition of proteasome activity was sustained, as was the case with 
genetic deletion of Psmc1 in megakaryocytes and platelets, mega-
karyocytes did not form proplatelets, and Psmc1fl/fl Pf4-Cre mice had 
severe thrombocytopenia. Mice with genetic ablation of Psmc1 in 
megakaryocytes and platelets also died shortly after birth. Taken 
together, these data provide compelling evidence that the protea-
some is critically involved in thrombopoiesis. The data also offer a 
strong explanation as to why multiple myeloma patients require cyclic 
treatment regimes of bortezomib in order to tolerate the drug (3, 12).
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development or blood/lymphatic vessel separation, which could lead 
to excessive bleeding (28). In this regard, several groups have shown 
that platelet C-type lectin-like receptor 2 (CLEC-2) receptors regulate 
lymphatic vascular development, and, like Psmc1fl/fl Pf4-Cre mice (29–
33), platelet-specific knockout of CLEC-2 results in postnatal lethality 
(32). It should also be noted that a very low threshold of platelet func-
tion sufficiently maintains vascular function (27, 33, 34), raising the 
possibility that Psmc1fl/fl Pf4-Cre mice produce dysfunctional platelets 
that are incapable of maintaining vascular integrity. Indeed, recent 
studies have demonstrated that immune-type receptors in platelets 
are critical for the prevention of inflammation-induced hemorrhage 
(35). Thus, it is entirely possible that in addition to being reduced in 
number, platelets from Psmc1fl/fl Pf4-Cre mice express an abnormal 
repertoire of proteins resulting in platelet dysfunction.
Studies in megakaryocytes revealed that genetic or pharma-
cologic interruption of proteasome activity led to accumulation 
of IțBĮ and RhoA. Although both proteins were upregulated, we 
found that the final stages of proplatelet formation required RhoA 
signaling rather than inhibition of NF-țB, as previously suggested 
(12). The inability to sprout proplatelets resembled studies in neu-
tion and types/concentrations of proteasome inhibitors between 
the studies may also explain the divergent results. Further studies 
are needed to resolve the in vivo pharmacology of proteasome inhi-
bition and its relation to thrombocytopenia. However, our present 
studies clearly showed that platelet counts rebounded at a slower 
pace in mice subjected to platelet depletion in the presence of bort-
ezomib. These data, in combination with the severe thrombocyto-
penia we observed in Psmc1fl/fl Pf4-Cre mice, demonstrated that the 
proteasome directly modulates platelet production.
We found that thrombocytopenia was more severe in Psmc1fl/fl 
Pf4-Cre mice compared with c-Mpl knockout mice (Supplemental 
Figure 12), which have normal life expectancies (27). Consistent with 
a marked reduction in platelet counts, Psmc1fl/fl Pf4-Cre mice had low 
hematocrits and hemorrhaging in the abdominal region. Occasional 
hemorrhaging was also observed in the brain, lymph nodes, and 
intestines. This suggests that severe thrombocytopenia is the primary 
driver of postnatal death in Psmc1fl/fl Pf4-Cre mice. Hemorrhaging 
in Psmc1fl/fl Pf4-Cre mice may occur because platelet numbers are 
simply too low to prevent bleeding. Alternatively, insufficient plate-
let counts in Psmc1fl/fl Pf4-Cre mice may result in abnormal vascular 
Figure 4. The proteasome 
regulates proplatelet formation 
through the RhoA signaling 
pathway. (A) Human megakaryo-
cytes were treated with vehicle 
or bortezomib, and total RhoA 
and GTP-bound RhoA were mea-
sured. Shown are representative 
Western blots and expression of 
RhoA or RhoA-GTP, as measured 
by densitometry, relative to vehi-
cle control. Data are mean ± SEM 
of 4 independent experiments. 
(B and C) Human megakaryo-
cytes were treated with vehicle, 
bortezomib, or bortezomib plus 
Y27632. (B) Western blot for 
phospho-MLC. (C) Representa-
tive confocal images of human 
megakaryocytes stained with 
WGA (red) and phalloidin (green). 
Arrows denote proplatelets. 
Scale bar: 50 ȝm. Also shown is 
the number of proplatelet-pro-
ducing megakaryocytes relative 
to vehicle control. Data are mean 
± SEM of 3 independent experi-
ments. (D) Representative trans-
mission images of mouse bone 
marrow–derived megakaryocytes 
treated with vehicle, bortezo-
mib, bortezomib plus Y27632, or 
bortezomib plus fasudil. Scale 
bar: 100 ȝm. Also shown is the 
number of proplatelet-producing 
megakaryocytes relative to 
vehicle control. Data are mean ± 
SEM of 3 independent experi-
ments. *P < 0.05 vs. vehicle;  
#P < 0.05 vs. bortezomib alone.
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rons, in which acute inhibition of the proteasome blocks activity-
dependent growth of new dendritic spines. It is not known what 
proteins are degraded by the proteasome in order to stimulate 
new spine growth; however, inactivation of RhoA leads to neurite 
outgrowth (36, 37). This suggests that, similar to megakaryocyte 
proplatelet formation, the proteasome may control neuronal out-
growth by degrading RhoA. Moreover, RhoA signaling has been 
shown to maintain normal megakaryocyte development, which is 
critical for platelet production (18).
Malfunction of the proteasome in human diseases may lead 
to aberrant platelet production or abnormal platelet generation. 
Disruption of proteasome activity could occur at multiple check-
points, since human megakaryocytes expressed the full reper-
toire of proteasome components at the mRNA level (Supplemen-
tal Table 1). Identifying the complete portfolio of target proteins 
degraded by the proteasome in megakaryocytes will shed addi-
tional light on the mechanisms that control thrombopoiesis and 
the phenotype of platelets as they enter the circulation. Under-
standing the functions of the proteasome in platelets, which is 
active and capable of degrading proteins (7–9), also requires fur-
ther investigation. From an immediate perspective, our present 
findings demonstrated that bortezomib directly inhibits protea-
some activity in megakaryocytes and thereby decreases platelet 
production. Our findings also established fasudil as a potential 
treatment for preventing and/or reversing bortezomib-induced 
thrombocytopenia in multiple myeloma patients. Additionally, 
inhibitors of the RhoA signaling pathway may have efficacy in 
the treatment of other thrombocytopenic disorders caused by 
abnormal platelet production, especially if the disease is driven 
by proteasome-dependent mechanisms.
Figure 5. Genetic ablation of proteasome activ-
ity in megakaryocytes causes severe throm-
bocytopenia and postnatal death. (A) Platelet 
counts at P1 in Psmc1fl/fl Pf4-Cre and Psmc1fl/wt 
mice, expressed relative to Psmc1fl/fl mice. Bars 
show mean ± SEM of 6 independent experi-
ments. *P < 0.05 vs. Psmc1fl/fl. (B) Mortality rates 
in Psmc1fl/fl, Psmc1fl/wt, and Psmc1fl/fl Pf4-Cre 
mice at P1 and P21. Shown are ratios of expected 
versus observed genotypes, determined by Ȥ2 
analysis, at P1 and P21  
(n = 88). *P < 0.05 vs. P1, determined by Ȥ2 distri-
bution table. (C) Hematocrits in Psmc1fl/fl Pf4-Cre 
relative to Psmc1fl/wt mice at P1. Data are mean 
± SEM of 6 independent experiments. *P < 0.05 
vs. Psmc1fl/wt. (D) Left: Images of Psmc1fl/wt and 
Psmc1fl/fl Pf4-Cre mice at P1. Evidence of bleeding 
was observed in the abdominal region (arrow). 
Middle and right: Limbs of Psmc1fl/wt and  
Psmc1fl/fl Pf4-Cre mice. Hemorrhaging was 
observed in the limb of the Psmc1fl/fl Pf4-Cre 
mouse (arrow). (E) Whereas P1 histological sec-
tions of Psmc1fl/wt mice demonstrated normal 
histology, bleeding was observed in the bladder 
and testis of a Psmc1fl/fl Pf4-Cre mouse. Boxed 
regions are shown at higher magnification at 
right. Scale bars: 100 ȝm.
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Methods
Differentiation of human and mouse megakaryocytes
Cord blood from normal full-term deliveries was obtained, and CD34+ 
hematopoietic progenitors were isolated and differentiated into mega-
karyocytes as previously described (38, 39). Mature megakaryocytes 
were placed on immobilized human fibrinogen–coated surfaces in 
the presence of specific inhibitors or their vehicle, and the number of 
megakaryocytes that possessed proplatelets was counted by an inde-
pendent blinded observer. On average, 12% ± 3% of vehicle-treated 
megakaryocytes had proplatelet extensions.
Mouse megakaryocytes were isolated from fetal liver as previ-
ously described (40). Mouse bone marrow–derived megakaryocytes 
were obtained using modifications of a published report (41). For the 
bone marrow megakaryocytes, C57BL/6 mice (8–10 weeks of age) 
were euthanized, and cells were obtained from the bone marrow 
of femur and tibia by flushing the bone marrow. Cells were homog-
enized by pipetting followed by passage through a 100-ȝm filter. The 
cell population was resuspended in 10% fetal bovine serum–supple-
mented DMEM with 2 mM L-glutamine, penicillin/streptomycin, and 
fibroblast condition media containing thrombopoietin. The cells were 
cultured for 5 days (37°C and 5% CO2), and mature megakaryocytes 
were layered over a bovine serum albumin (BSA) gradient as described 
previously (42). Fetal liver and bone marrow–derived megakaryo-
cytes were subsequently resuspended in culture media as described 
above, then placed on immobilized BSA or fibrinogen in the presence 
or absence of inhibitors, and megakaryocytes with proplatelets were 
counted. On average, 34% ± 1% of vehicle-treated fetal liver–derived 
megakaryocytes produced proplatelets. Proplatelet formation in vehi-
cle-treated bone marrow–derived megakaryocytes was 50% ± 1%.
Inhibitors used in these in vitro studies (all diluted in DMSO) 
included bortezomib (100 nM; Selleck Chem), Y27632 (10 ȝM; Sig-
ma-Aldrich), fasudil (10 ȝM; Selleck Chem), C3 transferase (10 ȝM; 
Cytoskeleton Inc.), SC-514 (0.5 ȝM; Calbiochem), MG132 (10 ȝM; Sig-
ma-Aldrich), and lactacystin (10 ȝM; Sigma-Aldrich). Inhibitors were 
administered at different times, as indicated in the figure legends.
Next-generation RNA-Seq
Fetal liver–derived megakaryocytes for RNA-Seq were provided by J. 
Thon (Harvard Medical School, Boston, Massachusetts, USA). RNA 
from human CD34-differentiated or fetal liver–derived proplate-
let-producing megakaryocytes was isolated and prepped for deep 
sequencing as previously described (43–45). In brief, RNA was pre-
pared for sequencing according to Illumina’s (DNA vision) TruSeq 
kit V2 for poly-A RNA. Libraries were sequenced 36 (human) and 50 
(mouse) base pairs on an Illumina sequencer. Reads were aligned 
using Novoalign (Novocraft Technologies) software followed by pro-
cessing, including RPKM assignment, using the USeq analysis pack-
age (46). The processed RNA-Seq data and aligned reads were depos-
ited in GEO (accession no. GSE58202; ref. 47).
Protein expression analyses and assessment of RhoA activity
Cell lysates were placed in laemmli buffer, proteins were separated by 
SDS-page, and IțBĮ and phospho-MLC (Cell Signaling) were analyzed 
by Western blotting. To measure RhoA activity, platelets were placed in 
Mg2+ lysis buffer supplemented with protease (Roche Applied Science) 
and phosphatase inhibitors (Sigma-Aldrich). A small portion of the 
lysate was retained as total cell lysate, and the rest was incubated with 
the assay reagent. GTP-bound forms were eluted from the assay reagent 
using Laemmli sample buffer. Total RhoA and RhoA-GTP bound pro-
tein were analyzed by Western blotting using a pulldown kit (Millipore).
Mouse in vivo studies
In vivo measurements of platelets. In Figure 1A, platelet counts were 
determined at various time points with a Hemavet 950 (Drew Sci-
entific). For platelet clearance, C57BL/6 mice were injected intra-
venously (i.v.) on day 0 with anti-GPIBȕ Dylight 488 (0.1 ȝg/g body 
weight; Emfret Analytics) and intraperitoneally (i.p.) with bortezo-
mib (2 mg/kg body weight) or its vehicle (10% DMSO in 0.9% saline). 
Blood samples (30 ȝl) were taken daily, diluted in Hanks balanced salt 
solution, and stained with a phycoerythrin-conjugated anti-mouse 
CD41 antibody (BD Biosciences), and clearance of Dylight 488–posi-
tive platelets was measured as previously described (48).
For estimation of platelet production, C57BL/6 mice were 
injected i.v. on day 0 with anti-GPIBĮ antibodies (3 ȝg/g body 
weight; Emfret Analytics) to deplete circulating platelets. On day 1, 
Figure 6. Platelet territories and proplatelets fail to form in PSMC1-
deficient megakaryocytes. (A) Whereas Psmc1fl/wt mouse megakaryo-
cytes showed a large cytoplasmic region compared with the nucleus, 
those from a Psmc1fl/fl Pf4-Cre mouse had less cytoplasm compared 
with the multilobed nucleus. Boxed regions are shown at higher 
magnification below, in which the demarcation membrane exhibited 
in the Psmc1fl/wt megakaryocytes (arrowheads) was not observed in the 
Psmc1fl/fl Pf4-Cre megakaryocyte. (B) Transmission images of mega-
karyocytes derived from Psmc1fl/wt and Psmc1fl/fl Pf4-Cre mice at P1. 
Proplatelet formation (arrows) was absent in Psmc1fl/fl Pf4-Cre mice. 
Scale bars: 2 ȝm (A); 100 ȝm (B).
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Pdgf-Cre-ER pups on P1, and then mortality was monitored from 
P2 to P21. For studies in adult Psmc1fl/fl Pdgf-Cre-ER mice, tamoxi-
fen was administered 8 weeks after birth. In these mice, fasudil 
(5 mg/kg) was injected i.p. to Psmc1fl/fl Pdgf-Cre-ER mice 4 and 48 
hours after tamoxifen administration, and blood was retrieved from 
tail veins on day 6 after tamoxifen to determine circulating plate-
let counts. In a subset of mice (n = 2 per treatment group), ex vivo 
assessment of proplatelet formation was performed. For these stud-
ies, mice were euthanized via CO2 asphyxiation followed by cervi-
cal dislocation. Femurs were isolated, and bone marrow cords were 
flushed with HEPES-tyrodes buffer with 100 U/ml penicillin/strep-
tomycin. Crude bone marrow cords were sliced into multiple sec-
tions, and buffer was replaced with HEPES-tyrodes buffer with 5% 
mouse serum and 100 U/ml penicillin/streptomycin. Bone marrow 
sections were then incubated at 37°C for 2 hours and stained with 
platelet counts were assessed to confirm depletion; shortly after, 
mice were treated i.p. with bortezomib or its vehicle as above. 
Blood samples (2 ȝl) were taken daily for the remainder of the 
experiment, and platelet counts were measured by flow cytometry 
as previously described (13).
Knockout of the proteasome in mouse megakaryocytes and platelets. 
Megakaryocyte and platelet ablation of proteasome activity was 
achieved by crossing Psmc1fl/fl mice (provided by J. Mayer, Baylor 
College of Medicine, Houston, Texas, USA) with Pf4-Cre or Pdgf-
Cre-ER mice (Jackson Labs), generating Psmc1fl/wt and Psmc1fl/fl Pf4-
Cre mice or Psmc1fl/wt and Psmc1fl/fl Pdgf-Cre-ER mice. Psmc1fl/fl mice 
were also used as controls in select studies. Knockdown was con-
firmed in megakaryocytes using an antibody against PSMC1 (Novus 
Biologicals), and platelet counts were assessed as recently described 
(49). Tamoxifen (0.25 mg/kg) was administered i.p. to Psmc1fl/fl 
Figure 7. Genetic deletion of Psmc1 in megakaryocytes is associated with increased RhoA protein and activity. (A) Representative Western blot 
of total RhoA and RhoA-GTP in megakaryocytes derived from Psmc1fl/wt and Psmc1fl/fl Pf4-Cre mice at P1. Also shown is densitometry quantification 
relative to Psmc1fl/wt control; for RhoA-GTP, megakaryocytes were isolated from 10 P1 mice, lysed, and then the lysates were pooled together for 
each pulldown experiment (see Methods). Data are mean ± SEM of 3 (total RhoA) and 2 (RhoA-GTP) experiments. *P < 0.05 vs. Psmc1fl/wt.  
(B) Bone marrow–derived megakaryocytes from Psmc1fl/wt and Psmc1fl/fl Pf4-Cre mice were treated with vehicle or fasudil, and the number of 
proplatelet-producing megakaryocytes was quantified and expressed relative to Psmc1fl/wt controls. Data are mean ± SEM of 3 independent experi-
ments. *P < 0.05 vs. vehicle-treated Psmc1fl/wt.
Figure 8. Inhibition of RhoA signaling rescues 
platelet counts in adult mice in which proteasome 
activity is conditionally deleted. (A) Tamoxifen was 
administered to adult Psmc1fl/wt and Psmc1fl/fl Pdgf-
Cre-ER mice, followed by treatment with fasudil or 
saline control (4 and 48 hours after tamoxifen). Shown 
are platelet counts at day 6 after tamoxifen admin-
istration relative to Psmc1fl/wt controls treated with 
tamoxifen alone. Data are mean ± SEM of 9 experi-
ments performed on independent mice. *P < 0.05 
as indicated. No significant difference was observed 
between groups treated with tamoxifen plus fasudil. 
(B) Representative images of Dylight 488–positive 
megakaryocytes present in crude bone marrow iso-
lated from Psmc1fl/wt and Psmc1fl/fl Pdgf-Cre-ER mice 
immediately after euthanasia. Bone marrow for these 
studies was isolated from a subset of the mice in A  
(n = 2 per treatment group). Scale bars: 100 ȝm.
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All data graphed relative to controls (Figures 2–5, 7, and 8 and Sup-
plemental Figures 4, 7, 10, and 13) were generated by comparing the 
average of the data set in each treated group with that of the control 
group (as the denominator). 
Study approval
The human studies were approved by the University of Utah’s Institu-
tional Review Board (IRB no. 392). All participating subjects provided 
informed consent. Cord blood from normal full-term deliveries was 
obtained after informed consent by the mothers (IRB no. 11919). The 
mouse studies were approved by the University of Utah’s Institutional 
Animal Care and Review Board (IACUC nos. 12-10002 and 12-11017) 
or by the Children’s Hospital in Boston (IACUC no. A3431-01).
Further information can be found in the supplemental material 
and citations therein (51, 52).
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anti-GPIBȕ Dylight 488. Megakaryocytes were imaged on a Nikon 
Eclipse TS100 fluorescence microscope and quantified by counting 
10 fields (×20) per well.
Measurement of blood hematocrit
Hematocrit was measured in Psmc1fl/wt and Psmc1fl/fl Pf4-Cre mice at P3. 
After anesthesia (ketamine-xylazine; 0.2 mg/g body weight), blood 
was acquired via the retro-orbital venous plexus. Blood was collected 
into heparinized capillary tubes and spun at 50,000 g for 10 minutes 
to obtain a hematocrit for each mouse.
Histopathology
Organs from P1 mice were collected and fixed in neutral buffered for-
malin. Tissues were embedded in paraffin, sectioned at 10 ȝm, and 
stained with hematoxylin and eosin (H&E). Slides were then assessed 
by a hematopathologist.
Electron microscopy
Femurs from mice were collected, and bone marrow was flushed into 
glutaraldehyde 2.5% in PBS. Fixed samples were kept at 4°C, shipped 
to the Hospital for Sick Children in Toronto, and further processed and 
imaged as previously described (50).
Statistics
For multiple-group comparisons, data were subjected to 1-way 
analysis of variance (ANOVA), and Tukey’s post-hoc test was used 
to assess statistical significance among groups. 2-way ANOVA with 
Newman-Keuls post-hoc test was used to assess statistical signifi-
cance for the data in Figure 8B. 2-tailed Student’s t test was used 
when comparisons were made between 2 groups. Differences in 
mortality were assessed by Ȥ2 test, and observed outcomes were 
graphed relative to calculated expected outcomes (Figure 5B and 
Supplemental Figure 13B). When possible, quantifications were 
done by a blinded observer. P values less than 0.05 were considered 
statistically significant.
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Human and Mouse Platelet Isolation.  Whole blood from humans or mice was drawn into acid-
citrate-dextrose (ACD) and platelets were isolated as previously described (39, 45).   Freshly-
isolated platelets were resuspended in M199 culture medium for each experiment.  
 
Assessment of human megakaryocyte activation and adhesion.  To measure megakaryocyte 
spreading and adhesion, day 13 CD34+ progenitor cell derived megakaryocytes were placed on 
immobilized human fibrinogen (100 µg/ml; Calbiochem-Novabiochem Corporation, San Diego, 
CA) coated glass cover slips and incubated 2-6 hours in the presence or absence of inhibitors 
(described above), controls (DMSO), or media alone.  After indicated time points, cells were 
fixed with 4% paraformaldehyde for 20 minutes at room temperature followed by 
permeabilization in 0.1% Triton-X 100 for 5 minutes.  Fixed and permeabilized cells were 
stained with Alexa fluor 488 Phalloidin, Alexa fluor 555 Wheat Germ Agglutinin (WGA), and TO-
PRO 3 (Life Technologies, Grand Island, NY).  Cells were imaged using an FV300 Olympus 
IX81 microscope (Melville, NY).  Adherent cells were quantified by counting five 20x fields per 
chamber. All quantifications were done by a blind observer.  ! To measure activation, CD34+ progenitor cell derived megakaryocytes were isolated as 
above.  Megakaryocytes were treated with thrombin and PAC-1 binding was measured as 
described previously by us (38).  Fibrinogen binding was also determined in megakaryocytes 






Ex vivo assessment of megakaryocyte numbers in bone marrow and spleen. A rabbit anti-
human von-Willebrand factor (vWF) antibody known to cross-react with murine vWF (Dako, 
Denmark) was used as the primary antibody to immunohistochemically stain megakaryocytes 
present in the bone marrow or spleen of Psmc1fl/wt and Psmc1fl/fl;Pf4cre mice.  A biotinylated 
horse anti-rabbit antibody was used as the secondary antibody, and color development was 
achieved with DAB substrate following the Vector Elite ABC kit protocols (Vector, Burlingame, 
CA).  Megakaryocytes, identified by vWF staining in conjunction with morphological features, 
were then quantified using an eyepiece reticle that delineates an area of tissue measuring 250 x 
250 µm at 400X (Klarmann Rulings Inc, Litchfield, NH).  The megakaryocyte concentration was 
expressed as number of megakaryocytes in an area of bone marrow or spleen measuring 250 x 
250 µm.  
 
Ex vivo assessment of platelet aggregation.  Platelet aggregation studies were performed as 
previously described (8).  Briefly, washed platelets were resuspended in HBSS with 0.5% 
human serum albumin and preincubated with bortezomib or vehicle control for 30 minutes at 
37oC.  Treated platelets were then stimulated with 0.05 U/ml or 0.2 U/ml thrombin and 
aggregation was monitored by transmittance (Chronolog) with stirring (600 rpm). 
 
Ex vivo assessment of mouse and human platelet activation.  Washed mouse platelets (1 x 106) 
were resuspended in M199 media, pretreated for 30 minutes with bortezomib or its vehicle, and 
then left alone or activated for 15 minutes with varying concentrations of U46619, convulxin, or 
Par4 in the presence of PE-JonA (Emfret Analytics, Eibelstadt, Germany), an antibody that 
recognizes the active form of integrin αIIbβ3.  Agonist-induced expression of surface P-selectin 
expression (Santa Cruz Biotech, Santa Cruz, CA) was also assessed by flow cytometry in 






 Washed human platelets (5x108 total) were resuspended in M199 medium containing 
100µg/ml of fibrinogen and were pretreated for 30 minutes with bortezomib or its vehicle. 
Platelets were then stimulated with U46619, ADP, or thrombin for 15 minutes in the presence of 
PAC-1 (BD Biosciences, Franklin, NJ), an antibody that binds to the active conformation of 



























Supplemental Figures and Table Legend 
 
Supplemental Figure 1. Bortezomib does not directly activate or alter Par4-induced activation 
in mouse platelets.   Washed mouse platelets were left alone or incubated with increasing 
concentrations of Par4.  After 15 minutes, JonA binding was assessed by flow cytometry.  The 
bars represent the mean±SEM of 3 independent experiments. 
 
Supplemental Figure 2. Inhibition of the proteasome ex vivo does not alter the function of 
mouse platelets.   Washed mouse platelets were pretreated with Bort or its Veh and 
subsequently stimulated with increasing concentrations of U46619 or convulxin as described in 
the Methods section.  After 15 minutes, JonA binding (A) or P-selectin surface expression (B) 
was assessed by flow cytometry.  The bars represent the mean±SEM of 3 independent 
experiments. 
 
Supplemental Figure 3. Inhibition of the proteasome ex vivo does not alter the function of 
human platelets.   Washed human platelets were pretreated with Bort or its Veh and 
subsequently stimulated with increasing concentrations of U46619, ADP, or thrombin as 
described in the Methods section.  After 15 minutes, PAC-1 binding was assessed by flow 
cytometry.  The bars represent the mean±SEM of 3 independent experiments. 
 
Supplemental Figure 4.  MG132 attenuates proplatelet formation.  Human megakaryocytes 
were left alone (NT – no treatment) or treated with MG132 and then analyzed by confocal 
microscopy (6 hours post-MG132).  The images show megakaryocytes stained with WGA (red) 
and phalloidin (green) where white arrows point to proplatelet extensions and yellow arrows 
point to non-proplatelet producing megakaryocytes.  Scale bar = 50µm. The bar graph on the 






cells compared to untreated cells.  The bars represent the mean±SEM of 3 independent 
experiments and the asterisk is p<0.05 compared to NT.    
 
Supplemental Figure 5.  Inhibition of the proteasome does not alter αIIbβ3 activity in human 
megakaryocytes.  (A) CD34+-derived human megakaryocytes were treated with Veh or Bort and 
binding of soluble fibrinogen (FGN), in the presence or absence of 0.05 U/ml of thrombin (Thr), 
was assessed as described in the Methods section. The bars represent the mean±SEM of 3 
experiments and the asterisk identifies p<0.05 when comparing megakaryocytes with and 
without Thr to one another.  There was no difference in soluble FGN binding when comparing 
Veh to Bort treated megakaryocytes. MFI = mean fluorescent intensity.  (B) PAC-1 binding to 
megakaryocytes in the presence of Bort, Veh, or Thr (0.05 U/ml).  The bars represent the 
mean±SEM of 3 experiments and the asterisk identifies p<0.05 compared to Thr-treated 
megakaryocytes.     
 
Supplemental Figure 6. Inhibition of the proteasome does not alter adherence of human 
megakaryocytes to fibrinogen. Human megakaryocytes were placed on immobilized fibrinogen 
for 1 hour in the presence of Veh or Bort.  The cells were analyzed by confocal microscopy and 
adhered megakaryocytes were counted in five different fields.  The bars represent the 
mean±SEM of 2 independent experiments.  
 
Supplemental Figure 7.  The proteasome regulates human proplatelet formation through the 
RhoA signaling pathway.  Human megakaryocytes were treated with Veh, Bort, or Bort + C3 
transferase and the change in the relative number of proplatelet producing megakaryocytes in 
treated groups compared to Veh was assessed.  The bars in this figure represent the 







Supplemental Figure 8.  Psmc1 protein is expressed in human and mouse megakaryocytes. 
Human CD34+-derived and mouse bone marrow derived proplatelet producing megakaryocytes 
lysates were separated by SDS-Page and protein for Psmc1 was assessed.  Lanes 1 and 2 
show Psmc1 protein expression levels in two independent human megakaryocyte samples.  
Lanes 3 and 4 show Psmc1 protein expression in two independent mouse megakaryocyte 
samples. 
 
Supplemental Figure 9.  Protein for Psmc1 is reduced in megakaryocytes, but not other 
tissues, isolated from Psmc1fl/fl;PF4cre. (A) Western blot of megakaryocyte lysates obtained 
from Psmc1fl/wt and Psmc1fl/fl;PF4cre mice. Protein for Psmc1 is shown in the top panel.  After 
Psmc1 protein levels were assessed, the gel was stained with coomassie blue. A coomassie 
stained region of this gel is shown in the bottom panel.  This image is representative of 4 
independent experiments.  (B) Western blot of Psmc1 protein expression in megakaryocytes, 
brain, heart, liver and thymus from Psmc1fl/wt and Psmc1fl/fl;PF4cre mice.  After Psmc1 protein 
levels were assessed, the gel was stained with coomassie blue. Coomassie stained regions for 
each tissue are shown in the bottom panel.   
 
Supplemental Figure 10. Genetic ablation of proteasome activity in megakaryocytes increases 
protein ubiquitination. The top left panel shows a representative western blot of ubiquitinated 
proteins in megakaryocytes derived from Psmc1fl/wt and Psmc1fl/fl;Pf4cre mice.  The 
corresponding coomassie image of this gel is shown directly below.   The bars in the right panel 
show the relative change in ubiquitin expression in megakaryocytes from Psmc1fl/fl;PF4cre mice 







Supplemental Figure 11. Deletion of Psmc1 in megakaryocytes does not alter the number of 
megakaryocytes found in the bone marrow or spleen. Sections of bone marrow and spleen were 
stained for von Willebrand Factor (vWF) and vWF positive megakaryocytes were assessed in 
Psmc1fl/wt and Psmc1fl/fl;PF4cre mice. The left panels show representative bone marrow and 
spleen tissue sections.  Higher magnification insets from the spleen tissue sections are shown 
at the very bottom. The red boxes indicate the region of the spleen selected for the inset. Scale 
bars for full images = 50µm.  Scale bars for insets = 20µm. In the far right panel, the number of 
megakaryocytes in the bone marrow and spleen were counted as described in the Methods 
section.  The bars on the right represent the mean±SEM of tissue sections from 3 Psmc1fl/wt and 
3 Psmc1fl/fl;PF4cre mice. 
 
Supplemental Figure 12. c-mpl and Psmc1fl/fl;PF4cre mice are thrombocytopenic, but platelet 
counts are lower in Psmc1fl/fl;PF4cre mice. Platelet counts at P3 in Psmc1fl/wt and 
Psmc1fl/fl;PF4cre mice were compared to platelet counts from  c-mpl knockout mice (c-mplko/ko) 
and their littermate controls (c-mplwt/wt).  As shown in this figure, thrombocytopenia is observed 
in both the c-mplko/ko and Psmc1fl/fl;PF4cre mice but is more severe in the Psmc1fl/fl;PF4cre mice.  
The bars represent the mean±SEM of platelet counts obtained from 6 mice for each 
experimental group.  The asterisk is p<0.05 between groups designated by the lines above the 
bars.  
 
Supplemental Figure 13. Inducible deletion of Psmc1 in Pdgfcre-ER mice at P1 results in 
thrombocytopenia and death.  (A) Relative changes in platelet counts in Psmc1fl/fl;Pdgf-creER 
mice compared to Psmc1fl/fl and Psmc1fl/wt mice.  Platelet counts were determined 1 day post-
tamoxifen.  The bars represent the mean±SEM of 3 independent experiments and the asterisk 






Psmc1fl/fl;Pdgf-creER mice treated with tamoxifen on postnatal day 1 (P1).  Mortality was 
assessed at postnatal day 2 (P2) and 21 (P21).  The bars represent a Chi-square analysis 
comparing the expected versus observed genotypes at P1 and P21 (n=82) where the asterisk 
denotes significance as determined by a Chi-square distribution table.  
 
Supplemental Figure 14. Bortezomib blunts human platelet aggregation in response to low 
dose thrombin. Washed human platelets were preincubated with Veh or Bort and stimulated 
with low dose (0.05 U/ml) thrombin in the left panel or high dose (0.2 U/ml) thrombin in the right 
panel. Aggregation was monitored by light transmittance using a Chronolog platelet 
aggregometer. The platelet aggregation tracings are representative of three independent 
experiments. 
  
Supplemental Table 1.  Expression of transcripts coding for proteasome subunits in human 
and mouse megakaryocytes. Poly-A RNA isolated from CD34+-derived human megakaryocytes 
and fetal liver derived mouse megakaryocytes were sequenced on an Illumina genome 
analyzer. Reads were aligned and RPKM (reads per kilobase per million) expression estimates 
were calculated as previously described (45).   RPKM values with a threshold at <0.3 identify 
mRNAs with expression levels above background (45, 52).   Transcripts listed are proteasome 
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Supplemental Table 1.  
  
Gene Human  CD34+ Megs 
Murine Fetal 
Liver Megs  
proteasome 26S subunit, ATPase, 1 2.07 38.73 
proteasome 26S subunit, ATPase, 2 30.23 16.62 
proteasome 26S subunit, ATPase, 3 112.71 44.12 
proteasome 26S subunit, ATPase, 4 90.42 26.15 
proteasome 26S subunit, ATPase, 5 143.93 41.51 
proteasome 26S subunit, ATPase, 6 13.60 40.92 
proteasome 26S subunit, non-ATPase, 1 58.30 25.59 
proteasome 26S subunit, non-ATPase, 2 95.75 43.05 
proteasome 26S subunit, non-ATPase, 3 113.65 15.10 
proteasome 26S subunit, non-ATPase, 4 67.07 85.09 
proteasome 26S subunit, non-ATPase, 5 8.08 12.86 
proteasome 26S subunit, non-ATPase, 6 103.13 31.87 
proteasome 26S subunit, non-ATPase, 7 73.95 32.28 
proteasome 26S subunit, non-ATPase, 8 115.63 128.93 
proteasome 26S subunit, non-ATPase, 9 24.49 5.45 
proteasome 26S subunit, non-ATPase, 10 22.52 20.26 
proteasome 26S subunit, non-ATPase, 11 64.91 33.28 
proteasome 26S subunit, non-ATPase, 12 25.27 22.85 
proteasome 26S subunit, non-ATPase, 13 73.65 39.99 
proteasome 26S subunit, non-ATPase, 14 39.55 19.04 
proteasome subunit, alpha type, 1 54.43 38.70 
proteasome subunit, alpha type, 2 22.37 33.71 
proteasome subunit, alpha type, 3 60.60 5.50 
proteasome subunit, alpha type, 4 92.04 28.32 
proteasome subunit, alpha type, 5 105.97 12.41 
proteasome subunit, alpha type, 6 80.73 116.02 
proteasome subunit, alpha type, 7 187.17 36.16 
proteasome  subunit, beta type, 1 166.42 182.02 
proteasome subunit, beta type, 2 71.94 47.88 
proteasome subunit, beta type, 3 125.76 8.63 
proteasome subunit, beta type, 4 224.93 91.72 
proteasome subunit, beta type, 5 67.47 38.21 
proteasome subunit, beta type, 6 114.32 38.13 
proteasome subunit, beta type, 7 123.10 51.79 
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cascade to disrupt vascular stability
Weiquan Zhu1,2*, Nyall R. London1,2,3*, Christopher C. Gibson2,4*, Chadwick T. Davis2,5, Zongzhong Tong6, Lise K. Sorensen2,
Dallas S. Shi2,5, Jinping Guo1,2,7, Matthew C. P. Smith1,2,3, Allie H. Grossmann2,8, Kirk R. Thomas1,2 & Dean Y. Li1,2,3,9,10
The innate immune response is essential for combating infectious
disease. Macrophages and other cells respond to infection by
releasing cytokines, such as interleukin-1b (IL-1b), which in turn
activate a well-described, myeloid-differentiation factor 88
(MYD88)-mediated, nuclear factor-kB (NF-kB)-dependent tran-
scriptional pathway that results in inflammatory-cell activation
and recruitment1–4. Endothelial cells, which usually serve as a
barrier to the movement of inflammatory cells out of the blood
and into tissue, are also critical mediators of the inflammatory
response5,6. Paradoxically, the cytokines vital to a successful immune
defence also have disruptive effects on endothelial cell–cell inter-
actions and can trigger degradation of barrier function and dis-
sociation of tissue architecture7–9. The mechanism of this barrier
dissolution and its relationship to the canonical NF-kB pathway
remain poorly defined. Here we show that the direct, immediate
and disruptive effects of IL-1b on endothelial stability in a human
in vitro cell model are NF-kB independent and are instead the
result of signalling through the small GTPase ADP-ribosylation
factor 6 (ARF6) and its activator ARF nucleotide binding site
opener (ARNO; also known as CYTH2). Moreover, we show that
ARNO binds directly to the adaptor protein MYD88, and thus
propose MYD88–ARNO–ARF6 as a proximal IL-1b signalling
pathway distinct from that mediated by NF-kB. Finally, we show
that SecinH3, an inhibitor of ARF guanine nucleotide-exchange
factors such as ARNO, enhances vascular stability and significantly
improves outcomes in animal models of inflammatory arthritis
and acute inflammation.
A defining characteristic of the cytokine-induced inflammatory
response is the destabilization of endothelial barriers resulting in vas-
cular permeability7–9. To dissect the pathway(s) involved in this tissue
disruption, we treated cultured monolayers of human dermal micro-
vascular endothelial cells (HMVEC-d) with IL-1b, and detected an
increase in endothelial permeability within 15min (Fig. 1a). The
canonical IL-1b pathway involves ligand-stimulated activation of
interleukin-1 receptor (IL-1R), which recruits MYD88 to its cytoplas-
mic tail10. The subsequent signalling cascade through IRAK1 results in
the phosphorylation of IkB-a by the IkB kinase (IKK) complex, lead-
ing to translocation of NF-kB to the nucleus and the eventual tran-
scription of target genes that promote inflammatory-cell responses3,4
(Supplementary Fig. 1). To test the involvement of this pathway in IL-
1b-induced vascular permeability, cells were treated with the IKK
inhibitor SC-514 (ref. 11). Although SC-514 prevented IL-1b-induced
nuclear localization of NF-kB, it was unable to rescue either IL-1b-
induced permeability or disruption of vascular endothelial (VE)-
cadherin surface localization (Fig. 1b, c and Supplementary Fig. 2a–c).
We also wonderedwhether IL-1b-induced vascular permeability required
other known MYD88-mediated downstream signalling mechanisms,
including ERK1/2, p38 and JNK (also known as MAPK3/MAPK1,
MAPK14 and MAPK8, respectively)12,13. Although ERK1/2, p38 and
JNK were activated by IL-1b stimulation of endothelial cells, small-
molecule inhibitors of each of these pathways were unable to prevent
IL-1b-induced vascular permeability or IL-1b-induced disruption
of VE-cadherin cell-surface localization (Supplementary Fig. 2d–h).
Although specific NF-kB targets, such as VEGFA, COX-2 (also known
as PTGS2) and the COX-2 product prostaglandin E2 aremodulated by
IL-1b, their activation had no effect on IL-1b-induced endothelial
permeability3,14,15 (Supplementary Fig. 3a–e). Finally, treatment with
actinomycin D or cycloheximide effectively inhibited transcription or
translation, respectively, of NF-kB targets, but did not blunt IL-1b-
induced permeability (Fig. 1d and Supplementary Fig. 3f, g). These
data strongly support a role for the immediate and destabilizing effects
of IL-1b on endothelial stability through signalling pathways inde-
pendent of NF-kB, transcription and translation.
IL-1b can disrupt VE-cadherin cell-surface localization by promo-
ting endocytic internalization9. We proposed that IL-1b might use
ARF6, a known regulator of adherens protein localization16,17.
Indeed, IL-1b activated ARF6 in HMVEC-d within 1min, a response
accompanied by increased endocytosis of VE-cadherin within 5min
and an increase in monolayer permeability within 15min (Fig. 1a, e
and Supplementary Fig. 4a, b). IL-1b treatment did not affect total VE-
cadherin messenger RNA or protein levels (Supplementary Fig. 4c, d).
Adenoviral-mediated overexpression of constitutively active ARF6
(ARF6(Q67L))18 elicited a dose-dependent increase in endothelial per-
meability, as well as a disruption of VE-cadherin cell-surface locali-
zation (Fig. 1f, g and Supplementary Fig. 4e, f). A similar dose-
dependent loss of total VE-cadherin was also observed, probably
through internalization and subsequent degradation (Supplementary
Fig. 4g). Interestingly, at lower doses of adenovirus at which permea-
bility was still induced, loss of total VE-cadherin was not observed, but
a dose-dependent loss of cell-surface VE-cadherin occurred (Fig. 1f–h
and Supplementary Fig. 4g). Moreover, short interfering RNA
(siRNA) knockdown of ARF6 enhanced VE-cadherin cell-surface
localization and prevented both IL-1b-induced disruption of VE-
cadherin and IL-1b-induced endothelial permeability (Fig. 1i–k and
Supplementary Fig. 4h, i). Collectively, these data link ARF6 as a
critical regulator of VE-cadherin trafficking by controlling cell-surface
localization and the immediate and disruptive effects of IL-1b-induced
vascular permeability.
The ARF6 activation state is decreased through interaction with
GTPase-activating proteins (GAPs) and increased through interaction
with guanine nucleotide-exchange factors (GEFs). Consistent with
this, treatment of endothelial cells with the ARF-GAP inhibitor
QS11 evoked an increase in ARF6–GTP, a decrease in VE-cadherin
cell-surface localization and increased permeability (Fig. 2a–d and
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Supplementary Fig. 5a, b)19. We noted that a class of ARF-GEFs, the
cytohesins, is highly expressed in multiple types of endothelial cells
(Supplementary Fig. 5c). Accordingly, treatment of HMVEC-d with
SecinH3, a cytohesin inhibitor, significantly increased endothelial cell-
surface localization of VE-cadherin (Supplementary Fig. 5d–f)20.
Notably, SecinH3 inhibited IL-1b-induced ARF6–GTP, as well as
IL-1b-induced disruption of VE-cadherin cell-surface localization and
endothelial permeability (Fig. 2e–g and Supplementary Fig. 5g, h).
To determine which GEF might be uniquely involved, we used
siRNA to knockdown CYTH1, ARNO and CYTH3 (coding for cyto-
hesins 1, 2 and 3, respectively) and GEP100 (also known as IQSEC1)
(Supplementary Fig. 6a), and found that only siRNA targeting ARNO
completely blocked IL-1b-induced endothelial permeability and pheno-
copied the knockdown of ARF6 (Fig. 2h and Supplementary Fig. 6b).
Furthermore, ARNO siRNA inhibited IL-1b-induced ARF6–GTP
formation, IL-1b-induced disruption ofVE-cadherin cell–cell contacts
and IL-1b-induced internalization of surface VE-cadherin (Fig. 2i, j
and Supplementary Fig. 6c, g); all of these effects were rescued by the
expression of siRNA-resistant ARNO (Supplementary Fig. 6d–g). In
cells treated with ARNO siRNA, viral expression of siRNA-resistant
ARNO, but not viral expression of siRNA-resistant ARNO(E156K)
(carrying a mutation in the Sec7 domain), rescued the disruption of
IL-1b-induced ARF6–GTP formation and permeability21 (Supplemen
tary Fig. 6d, e). These data demonstrate that ARNO is a critical ARF-
GEF necessary for IL-1b-induced activation of ARF6 and subsequent
induction of vascular permeability, but does not rule out the role of
other GEF family members in similar responses in different cell types
or in response to different cytokines.
The signalling components in the NF-kB pathway downstream of
IL-1b-induced activation of IL-1R are well characterized (Supplemen-
tary Fig. 1). Although the inhibition of the NF-kB pathway at the
level of IRAK1 by siRNA did not inhibit IL-1b-induced ARF6 acti-
vation, siRNA knockdown of MYD88 inhibited both IL-1b-induced
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Figure 2 | Inhibition of ARF-GAPs and ARF-GEFs affect ARF6 activation
and VE-cadherin localization. a–d, HMVEC-d treated with QS11, showing
whole-cell lysates precipitated with GST–GGA3 and immunoblotted for
ARF6 (a), membrane fractions immunoblotted for VE-cadherin
(b), immunofluorescence for VE-cadherin (red) (c) and permeability to HRP
(d). e–g, HMVEC-d treatedwith IL-1b and SecinH3, showing immunoblotting
for ARF6 (e), immunofluorescence for VE-cadherin (f) and permeability to
HRP (g). h–j, HMVEC-d treated with anti-ARNO siRNA and stimulated with
IL-1b, showing permeability to HRP (h), GST–GGA3 precipitation and ARF6
immunoblotting (i) and immunofluorescence of VE-cadherin (j). Arrow
denotes less cell-surfaceVE-cadherin.n$ 3; error bars denote s.e.m. *P, 0.05,
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Figure 1 | Immediate effects of IL-1b are NF-kB independent and ARF6
dependent. a–d, Monolayers of HMVEC-d stimulated with IL-1b and assayed
for permeability to horseradish peroxidase (HRP) over time (a), permeability to
HRP following 2-h treatmentwith SC-514 (b), immunofluorescent localization
of VE-cadherin (c) and permeability to HRP after 30-min treatment with
actinomycin D or cycloheximide (d). e, IL-1b-stimulated HMVEC-d lysates
were precipitated with glutathione S-transferase (GST)–GGA3 and
immunoblotted forARF6. f–i, HMVEC-dmonolayers infectedwith adenovirus
(Ad) containing empty vector (null), green fluorescent protein (GFP) or
ARF6(Q67L), showingpermeability (f) andVE-cadherin localization (g) (green
denotes ARF6 expression). Membrane fractions from adenoviral-vector-
infected (h) or ARF6-siRNA-treated (i) HMVEC-d were immunoblotted for
VE-cadherin. j, k, ARF6-siRNA-treated HMVEC-d stimulated with IL-1b,
showing VE-cadherin localization (j) (arrows denote disrupted VE-cadherin
cell-surface localization) and permeability (k). A.U., arbitrary unit; DMSO,
dimethylsulphoxide; IB, immunoblot; TCL, total cell lysate. n$ 3; error
bars denote s.e.m. *P, 0.05, **P, 0.01, ***P, 0.001, ****P, 0.0001.
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IL-1b-induced signalling at the point of MYD88 (Fig. 3a–c and
Supplementary Fig. 7a, b). The proposed bifurcation was further
verified by the pharmacological uncoupling of the two pathway arms:
although SecinH3 blunted IL-1b-induced permeability, it did not
significantly inhibit IL-1b-induced NF-kB nuclear localization or
NF-kB-dependent expression or localization of cell-surface adhesion
molecules (Fig. 3d and Supplementary Fig. 7c, d). Furthermore,
SecinH3 was unable to inhibit IL-1b-induced polymorphonuclear
leukocyte rolling and adherence under shear stress on an endothelial
monolayer (Supplementary Fig. 7e). Mechanistic support for this
novel signalling arm was provided by the demonstration of an inter-
action between MYD88 and ARNO by co-immunoprecipitation in
both overexpression and endogenous settings (Fig. 3e, f). Our hypo-
thesis that ARNO is the critical GEF in IL-1b-induced permeability in
endothelial cells was further strengthened by our inability to detect an
interaction betweenMYD88 and other potentially relevantARF-GEFs
including CYTH1, CYTH3 and GEP100 (Supplementary Fig. 7f, g).
An effective therapeutic strategy to combat numerous inflammatory
conditions is to target pro-inflammatory cytokines proximal to the NF-
kB pathway. However, this strategy can result in undesired pleiotropic
effects. We wanted to know whether targeting a single arm in this
pathway—the one mediated by ARNO–ARF6—could inhibit acute or
chronic inflammation in vivo in two animal models of inflammation.
The first model we tested was rheumatoid arthritis, a disease characte-
rized by a dysregulated cytokine response causing excessive inflam-
mation and tissue damage and treated therapeutically in humans with
the anti-cytokine tumour necrosis factor receptor (TNFR)–Fc fusion
protein etanercept (Enbrel)22–25. A standard animal model of arthritis
through which a TNFR fusion approach has been proven effective is
collagen-induced arthritis (CIA)24–26. Exposure of animals to the cyto-
hesin inhibitor SecinH3 after the onset of CIA reduced vascular per-
meability in the joints, but had no effect on global cytokine levels at 24 h
after treatment initiation (Fig. 4a and Supplementary Fig. 8a, b). In
addition, a significant inhibition in the increase in arthritic index,
comparable to that achieved by treatment with Enbrel, was observed.
The arthritic index is a scoring system determined by the number of
digits or joints that are oedematous or erythematous. The significance
of our findings was verified by histologic scoring of inflammation,
pannus development, cartilage damage and bone damage (Fig. 4c,
d). A similar effect of SecinH3 was confirmed in a second model of
inflammation, the carrageenan air-pouch model. Six hours after an
inflammatory stimulus, a time at which substantial inflammation was
induced in the positive controlmice, treatment with SecinH3 decreased
exudate volume as well as leukocyte concentration in the exudates
(Supplementary Fig. 8c, d). Collectively, these data identify MYD88–
ARNO–ARF6 as a valid target for inflammatory conditions confirming
a relevant role for manipulation of this pathway in vivo to modulate


























































































































































































Figure 3 | The immediate IL-1b-induced permeability pathway diverges at
MYD88. a, IRAK1-siRNA-treated HMVEC-d, stimulated with IL-1b,
subjected to ARF6–GTP pull-down and immunoblotted for ARF6.
b, c,MYD88-siRNA-treated HMVEC-d stimulated with IL-1b, showing
permeability and ARF6 activation. d, NF-kB p65 (also known as RELA)
immunofluorescence in HMVEC-d stimulated with IL-1b and SecinH3.
Arrows denote nuclear localization. e, Cell lysates from Ad-ARNO–MYC-
infected HMVEC-d immunoprecipitated (IP) with anti-MYC antibodies and
immunoblotted with anti-MYD88 antibodies. f, Lysates from HMVEC-d
immunoprecipitated with anti-MYD88 antibodies and immunoblotted with








































































































































Figure 4 | Inhibition of ARF-GEFs decreases collagen-induced vascular
permeability and arthritis inmice. a, Arthritis-induced vascular permeability
in the joint measured by Evans Blue leak 7 days after treatment initiation in the
presence of SecinH3 or Enbrel. n5 14 per group. b, Chronological arthritic
assessment. n5 10 per group. Significance values are measured against CIA
plus vehicle. c, Haematoxylin and eosin staining of sections through joints. Bn,
bone; HC; hyaline cartilage; JS, joint space; Pn, inflamed pannus. Asterisk
denotes cartilage and bone loss; arrows denote eroded cartilage. d, Summary of
histological changes of inflammation, pannus, cartilage and bone damage of
indicated treatment. Control, n5 5; Enbrel and SecinH3, n5 10. Error
bars denote s.e.m. *P, 0.05, **P, 0.01, ***P, 0.001, ****P, 0.0001 versus
disease group.
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Chronic inflammation causes tissue destruction through dysregu-
lated cytokine release, inflammatory cell recruitment and vascular
permeability; yet each of these mechanisms has critical roles in many
physiologic processes, including the immune response5,7. We have
identified a novel pathway that uncouples cytokine effects on vascular
stability from other critical functions of the canonical NF-kB tran-
scription program (Supplementary Fig. 1). Our model suggests the
potential for inhibition of vascular leak without modulation of
immune-cell adhesion or other critical NF-kB-dependent responses.
The activation of many inflammatory cytokine receptors disrupts
cell–cell interactions, precipitating tissue oedema and destruc-
tion5,7,9,27. Toll-like receptors and the interleukin receptor also use
MYD88, and the mechanism described here may well apply3,10.
Interestingly, TNFR1 (also known as TNFRSF1A) does not use
MYD88 yet still activates ARF6–GTP after stimulation (Supplemen-
tary Fig. 9). Whether ARNO or another ARF-GEF binds directly to
TNFR1 or its adaptor protein TRADD is unknown, as is the possibility
that ARF-GEF–ARF6–cadherin serves as a common signalling mo-
dule exploited by multiple cytokines. Although this study focused on
the endothelium, the concept of cytokine receptor–ARF–cadherin
may also apply to the epithelial barrier, which expresses these consti-
tuents and is also compromised by cytokines including IL-1b16.
Inhibition of this novel vascular-stability pathway, which is aimed at
enhancing the resilience of the host to the cytokine response, shows
effects commensurate to those of class-leading drugs that target cyto-
kines upstream of NF-kB and seek to blunt the cytokine response of
the immune system outright. This approachmay be particularly useful
in arthritis, as the current medical therapy can render a patient immu-
nocompromised and susceptible to reactivation of infectious disease
such as tuberculosis28. Application of these findings to other diseases
characterized by excessive acute or chronic inflammatory states,
including sepsis, Crohn’s disease, ulcerative colitis, scleroderma and
psoriasis, should also be considered9,29,30.
METHODS SUMMARY
Transwell permeability.HMVEC-d cells were seeded on 1.0-mmCostar transwell
inserts coated with fibronectin. Cells were grown to confluency and treated with
SecinH3 for 3 h or MAPK/NF-kB/transcription/translation inhibitors for 30min
followed by treatment with 10 ngml21 IL-1b. Alternatively, cells were infectedwith
Ad-GFP or Ad-ARF6(Q67L) for 48h. siRNA knockdown was performed as
described in Supplementary Methods, and cells were treated with IL-1b 72 h after
the second siRNA transfection. Twohours later,HRPwas added to the top chamber
at a final concentration of 100mgml21.Mediumwas removedafter 60min fromthe
lower chamber. For time-course transwell assays and transcription/translation-
inhibitor experiments (Fig. 1a, c, d), HRP was added to the insert at the same time
as IL-1b. Transwell inserts weremoved to fresh wells after each time point, and the
concentration of HRP in the bottom chamber was measured for monolayer per-
meability.HRPwas assessedusingmedia samples obtained from the lower chamber
incubatedwith 0.5mMof guaiacol and 0.6mMH2O2. Spectrophotometric analysis
of absorbance at 490 nm provided a quantitative evaluation of the amount of HRP
that crossed the membrane. Data are presented as mean6 s.e.m. of at least three
independent experiments performed in quadruplicate.
A detailed description of all methods is provided in Supplementary Information.
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6XSSOHPHQWDU\)LJXUH  ,/ȕLQGXFHGSHUPHDELOLW\LVLQGHSHQGHQWRI1)ț%WUDQVFULSWLRQDQGLWVWDUJHWV
(a) +09(&' FHOOV WUHDWHGZLWK ,/ȕ IRU     RU  KRXUV ZHUH VXEMHFWHG WR TXDQWLWDWLYH 573&5 WR







SUHVHQFHRUDEVHQFHRI$FWLQRP\FLQ' (g)1)ț% WUDQVFULSWLRQDO WDUJHWV ,/0&3DQG*52DSURWHLQ OHYHOV
ZHUH FKHFNHG LQ WKH FRQGLWLRQHGPHGLD IURP+09(&'FHOOV WUHDWHGZLWK ,/ȕ LQ WKHSUHVHQFHRU DEVHQFHRI
$FWLQRP\FLQ'DQG&\FORKH[LPLGHE\(/,6$
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Supplementary Figure 5.  ,QKLELWLRQRI$5)*$36RU$5)*()VZLWKVPDOOPROHFXOHVGHFUHDVHVRULQFUHDVHV
9(FDGKHULQFHOOVXUIDFHORFDOL]DWLRQUHVSHFWLYHO\  
(a)4XDQWL¿FDWLRQRISODVPDPHPEUDQH9(FDGKHULQDV VKRZQ LQ)LJXUHF E7UDQVHQGRWKHOLDO UHVLVWDQFHZDV
PHDVXUHGE\(&,6 LQ+09(&'FHOOV WUHDWHGZLWK'062RU46  F+09(&'+XPDQUHWLQDOHQGRWKHOLDO
FHOOV +5(&DQG+XPDQXPELOLFDOYHLQHQGRWKHOLDOFHOOV +89(&ZHUHDQDO\]HGE\TXDQWLWDWLYH573&5IRU
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WKDW*(3 LV UHJXODWLQJSHUPHDELOLW\ LQGHSHQGHQW RI DQ ,/ȕSDWKZD\ F4XDQWL¿FDWLRQRI)LJXUHN  (d) 
+09(&'WUHDWHGZLWKARNORUFRQWUROVL51$ZHUHVWLPXODWHGZLWK,/ȕLQWKHSUHVHQFHRUDEVHQFHRI$G
$5120<&RU$G1XOO WKHQ DVVD\HG E\*73$5)SXOOGRZQ DQG LPPXQREORWWHGZLWK$5) DQWLERGLHV (e) 
+09(&'WUHDWHGZLWKARNORUFRQWUROVL51$ZHUHLQIHFWHGZLWK $G1XOO RUARNO VL51$UHVLVWDQW$G$512
0<&WKHQVWLPXODWHGZLWK,/ȕDQGDVVD\HGE\WUDQVZHOOSHUPHDELOLW\DVVD\I4XDQWL¿FDWLRQRIFHOOVXUIDFH
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6XSSOHPHQWDU\ )LJXUH   7KH ,/ȕLQGXFHG SHUPHDELOLW\ SDWKZD\ GLYHUJHV IURP WKH FDQRQLFDO1)ț%
SDWKZD\DW0<' 
(a) /\VDWHV IURP+09(&'FHOOV WUDQVIHFWHGZLWK IRAK1 RU FRQWURO VL51$ZHUH LPPXQREORWWHG IRU ,5$. 
E/\VDWHVIURP+09(&'FHOOVWUDQVIHFWHGZLWKMYD88 RUFRQWUROVL51$ZHUHLPPXQREORWWHGIRU0<' 
F )OXRUHVFHQFHDFWLYDWHG FHOO VRUWLQJ IRU (VHOHFWLQ ,&$0 DQG 9&$0 FHOO VXUIDFH ORFDOL]DWLRQ RI 
+09(&'VWLPXODWHGZLWK,/ȕLQWKHSUHVHQFHRI'062RU6HFLQ+(d)4XDQWLWDWLYH573&5IRUE-selectin, 
ICAM-1 DQGVCAM-1RI+09(&'VWLPXODWHGZLWK,/ȕLQWKHSUHVHQFHRI'062RU6HFLQ+(e)4XDQWL¿FDWLRQ
RI KXPDQ SRO\PRUSKRQXFOHDU OHXNRF\WH UROOLQJ DQG DGKHUHQFH WR D +09(&'PRQROD\HU XQGHU VKHDU VWUHVV
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Human dermal microvascular endothelial cells (HMVEC-D) were purchased at passage 0 from 
Lonza and used at passages 2-6.  SecinH3, ERK1/2 signal pathway inhibitor (U0126), P38 signal 
pathway inhibitor (SB203580), JNK signal pathway inhibitor (JNK Inhibitor II), and NF-B 
signal pathway inhibitor (SC-514) were from Calbiochem.  QS11 was from Sigma. Rabbit anti-
VE-cadherin antibody, rabbit anti-MYD88 antibody (#3699 for western blot, #4283 for 
immunoprecipitation), rabbit anti-IRAK1 antibody, rabbit anti-p-ERK1/2, rabbit anti-p-P38, 
rabbit anti-p-JNK antibody, rabbit anti-ERK1/2, rabbit anti-P38 antibody, rabbit anti-JNK 
antibody and rabbit anti-NF-B P65 antibody were from Cell Signaling.  Mouse anti-ARF6 
antibody was from Millipore.  Mouse anti-ARNO antibody was from Abnova.  ARF6 siRNA, 
ARNO siRNA, MYD88 siRNA and IRAK1 siRNA were from Qiagen.    
 
Transfection and siRNAs 
 
siRNAs were diluted in 12.5% HiPerFect Transfection Reagent (Qiagen) in Optimem 
(Invitrogen) and incubated 10-20 minutes at room temperature. As siRNAs were sitting, passage 
3-4 HMVEC-D cells were passaged and resuspended in EGM2-MV (Endothelial Cell Basal 
medium-2 supplied with EGM®-2 MV SingleQuots®, Lonza) and combined with siRNAs such 
that the final concentration of siRNA was 30nM (all targets). The cells were plated, allowed to 
grow overnight and then the growth media was replaced. Three days after the initial transfection, 
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The following is a table of all siRNAs used, their catalogue numbers, sequence, the location 
within the gene the siRNA targets, and average knockdown observed by western blot. 
Gene Catalogue 
Number 
Target sequence (5’-3’) Region Mean 
knockdown 
ARF6 SI02757286 CAACGTGGAGACGGTGACTTA exon 77% 
ARNO SI00061299 CACGCTGTTGGTAATCTTATT 3’ UTR 63% 
Cytohesin-1  SI04217185 CGGGACAGAGGTTCCGGATAA 3’ UTR 93% 
Cytohesin-3 SI00061257 CAGCATGTTGTGCTCGGACAA 3’ UTR 99% 
MYD88 SI00300909 AACTGGAACAGACAAACTATC exon 87% 
IRAK1 SI00605262 CCGGGCAATTCAGTTTCTACA exon 83% 
 
Protein expression constructs 
The coding sequence of full-length MYD88 (BC023589), ARNO (BC038713), CYTH-1 
(BC038385), CYTH-3 (BC028717) and GEP100 (BC010267) were amplified by PCR from 
IMAGE cDNA clones and ligated into a pcDNA3.1 vector after enzyme digestion.  The ARNO, 
CYTH-1, CYTH-3 and GEP100 constructs contained both MYC and HIS epitopes, while the 
MYD88 construct contained an HA epitope.   
Subcellular fractionation 
Subcellular fractionation was performed as previously described9.  Briefly, HMVEC-D cells 
were infected with adenovirus for 48 hours, stimulated with QS11 for 3 hours, or stimulated with 
SecinH3 for 2 hours.   Alternatively, cells were transfected with siRNA as described above.  The 
monolayer was washed two times with ice-cold phosphate-buffered saline (PBS) containing Ca2+ 
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protease inhibitors (Roche) and phosphatase inhibitors (Sigma), and dithiothreitol 1mM].  After 
the third wash, cells were homogenized in a Dounce homogenizer using 20 strokes.  The 




The resuspended pellet was centrifu?=<9L
?>GJEAFML=K9LX
9F<L@=KMH=JF9L9FL
was saved as a soluble membrane fraction.  To obtain the total cell lysate, an aliquot of cellular 
material was set aside before Dounce homogenization.  RIPA buffer was added to this aliquot 
and theFL@=EAPLMJ=O9K;=FLJA>M?=<9L
?>GJEAFML=K9LX/@=J=KMDLAF?
supernatant was saved for use as total cell lysate.  Densitometry was performed on at least three 
independent experiments and data are presented as mean ± SEM. 
ARNO Rescue Experiment 
=DDK106 in a 10 cm dish) were first transfected with ARNO siRNA (SI00061299, Qiagen) 
at 30nM and changed to fresh media 24 hours after the transfection. The siRNA was directed 
against sequences in the 3’ UTR of the endogenous ARNO mRNA.  48 hours after the media 
change, cells were harvested and underwent a second transfection with the same siRNA at the 
K9E=<GK==DDKO=J=L@=FAF>=;L=<OAth either an Ad-ARNO (WT) or Ad-ARNO (E156K) virus 
(5107 p.f.u.ml-1) 36 hours after the second siRNA transfection and incubated for 36 hours2.  The 
adenoviral vectors expressing human ARNO (or mutant ARNO) fused to a (4-epitope tag did 
not contain a 3’UTR ARNO sequence, and was thus predicted to be resistant to the siRNA.  
ARF6-GTP pull down assay:  ARF6-GTP pull-down assays were performed as described21.  
JA=>DQ
#(1 -D cells were pre-LJ=9L=<OAL@.=;AF#>GJ@GMJK>GDDGO=<:QLJ=9LE=FLOAL@
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10ng/mL IL-1.  Alternatively, cells were transfected with siRNA as described above.  Cells 
were treated with IL-1 72 hours after the second siRNA transfection for 5 minutes. After 
treatment, media was aspirated and cells were rinsed with chilled Ultrasaline. Dishes were frozen 
on dry ice.  Following thawing, ARF6 pulldown lysis buffer [Tris-HCl 50mM, NaCl 100mM, 
MgCl21mM, NP-40 1%, glycerol 10%, protease inhibitors (Roche) and phosphatase inhibitors 
(Sigma)] were added to cells.  Lysates were centrifuged and supernatants were added to GGA3-
conjugated beads (Cell Biolabs, sta-40706), and agitated at 4°C for 60 minutes.  Beads were 
washed in ARF6 pulldown lysis buffer and resuspended in 2X Laemmli prior to loading on 15% 
SDS-PAGE gels. A fraction of the cell lysate was withheld for use as a measure of total ARF6 in 
each sample. Data are presented as mean ± SEM of at least three independent experiments.    
Quantitative PCR 
Total RNA was extracted from cells using the RNeasy plus mini kit (Qiagen) according to 
manufacturer’s instructions.  RNA was converted to cDNA using RETROscript® kit (Ambion).  
Quantitative RT-PCR was performed using TaqMan probes (CYTH1, Hs00245092; ARNO, 
Hs00244669; CYTH3, Hs00188456; CYTH4, Hs00203581; IQSEC1, Hs00208333; IQSEC2, 
Hs00390333; IQSEC3, Hs01006522; EFA6A, Hs00160539; EFA6B, Hs00260268; EFA6C, 
Hs00209633; EFA6D,Hs00202892; VEGFA, Hs00900055; ICAM1, Hs00164932; VCAM1, 
Hs01003372; IL-6, Hs9999032; TNF, Hs01113624_g1; Cox2, Hs00153133; VE-cadherin, 
Hs00901463; E-selectin, Hs00174057_m1) and the ABI Prism 7900 HT Real-Time PCR System 
(Applied Biosystems).  Quantification was performed using a human brain cDNA standard curve 
and normalized to 18S rRNA. Data are presented as mean ± SEM of four duplicates from at least 
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Immunofluorescence 
10,000 HMVEC-D cells were seeded onto 8 well chamber slides coated with human fibronectin. 
Cells were pre-treated with small molecule inhibitors of NF-B or MAPK for 30 minutes or 
SecinH3 for 3 hours followed by treatment with 10 ng/ml IL-1 for 2 hours.  Alternatively, cells 
were infected with 1105-1108 p.f.u.ml-1 of the indicated adenovirus for 48 hours. For siRNA 
knockdown experiments, cells were harvested 72 hours after the first siRNA transfection, re-
transfected with the same siRNA a second time and seeded onto chamber slides. 72 hours after 
the second siRNA transfection, cells were treated with IL-1 for 2 hours. Cells were fixed, 
permeabilized, blocked with normal donkey serum and stained for VE-cadherin or NF-B p65.  
The only exception to this protocol was for Supplementary Fig. 6f, where permeabilization was 
not performed in order to increase the signal of cell-surface VE-cadherin.  Images are maximum-
Z-projections of confocal images acquired at 0.3 µm z-section intervals.  Image acquisition 
settings were identical for all images.  Images are representative of at least 3 independent 
experiments. Quantification was performed using a custom Image-J macro that imported images, 
applied a threshold to exclude all but intensely-stained areas, and returned this area as an output.  
Identical threshold and size restriction values were used to analyze all images. Data are presented 
as mean ± SEM of at least three independent experiments. 
Immunoprecipitation 
Immunopreciptation assays were performed as described9.  Briefly, HMVEC-D cells were 
treated with 10 ng/ml IL-1 for 1 and 5 minutes. For Figure 3e, HMVEC-D cells were infected 
with 1  107 p.f.u.ml-1 Ad Null or Ad-ARNO-MYC 48 hours before IL-1 treatment. Cells were 
then washed with ice-cold PBS and lysed with ice-cold lysis buffer (Tris-HCl 50 mM, NaCl 
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250mM, NP-40 1%, and glycerol 10% with protease inhibitors and phosphatase inhibitors). Cell 
lysates were centrifuged for 15 minutes at 13,000g and the supernatants saved. A BCA assay 
(Pierce) was used to determine protein concentrations. Lysates were incubated with 8 mg of the 
indicated antibody and protein A/G–Sepharose (Santa Cruz Biotechnology) for 1 hour at 4°C.  
Beads were then washed 5 times in lysis buffer. The immunoprecipitates were assayed by 
western blot analysis using Peroxidase-conjugated AffiniPure Light Chain Specific secondary 
antibody for signal detection. Data represents at least 3 independent experiments. 
Biotinylation Assay 
HMVEC-D cells were transfected with ARNO siRNA or control siRNA and then infected with 
Ad null or Ad-ARNO (as described), and grown to 100% confluence on 100-mm dishes. Cells 
were washed with ice-cold PBS three times and labeled with EZ-link Sulfo-NHS-SS-Biotin 
(Thermo) at 0.5mg/ml in PBS for 30 minutes on ice. Excess Biotin was removed by washing 
with glycine in PBS two times on ice. The cells were then incubated with 10 ng/ml IL-1 and 0.6 
mM Primaquine (MP Biomedicals) at 37°C for 30 minutes; they were then exposed to GSH 
buffer (Glutathione 50mM, NaOH 75mM, NaCl 75mM, EDTA 1mM, BSA 0.1%, PH 9.0) on ice 
for 20 minutes to remove surface biotin. GSH was then quenched by washing with 5 mg/ml 
iodoacetamide in PBS. After an additional wash with ice-cold PBS, cells were lysed in NP-40 
buffer (Tris-HCl 50 mM, NaCl 150 mM, MgCl2 1mM, NP-40 1%, Glycerol 10%) with a 
protease inhibitor cocktail on ice. Cell lysates were centrifuged at 14,000 rpm for 15 minutes and 
supernatant was incubated with High Capacity Streptavitin Agarose Resin (Thermo) for 60 
minutes at 4°C. Beads were washed with NP-40 lysis buffer three times. Bound proteins were 
released in 2Laemmli buffer with 5% -mercaptoethanol at 95°C and internalized VE-cadherin 
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Transendothelial resistance 
Transendothelial resistance was measured by Electric Cell-substrate Impedance Sensing (ECIS).  
An 8W10E+ electrode culture array (Applied Biophysics) was coated with 10 g/mL human 
fibronectin.  5 x 104 HMVEC-D per well were seeded in complete media onto the electrode 
culture array and monitored until a stable monolayer formed.  A stable monolayer was indicated 
by a capacitance <10 nF at 6.4 x 104 Hz and a stable resistance over several hours at 4 x 103 Hz.  
Cells were pre-treated with SecinH3/Avastin for 3 hours or MAPK/NF-B inhibitors or 
Indomethacin or PGE2 for 30 minutes followed by treatment with 10 ng/ml IL-1 (unless 
otherwise indicated).  Alternatively, cells were infected with Ad-GFP or Ad-ARF6 (Q67L) 
adenoviruses.  Resistance across the monolayer using alternating current at a frequency of 4 x 
103 Hz was measured by 40 electrodes per well (1000-2000 cells) using the ECIS-Z system 
(Applied Biophysics) and reported in Ohms or normalized to control treatment or initial 
resistance.  Conditioned media was collected from cells undergoing ECIS (Supplemental Figure 
2e) at 16 hours after treatment with IL-1 in the presence of DMSO or inhibitors.  PGE2 
concentration was calculated using the PGE2 Express EIA kit from Cayman Chemical (500141) 
according to manufacturer’s instructions.  Data are representative of at least 3 independent 
experiments or represented as mean ± SEM. 
Transwell permeability 
HMVEC-D cells were seeded on 1.0 µm Costar transwell inserts coated with fibronectin.  Cells 
were grown to confluency and treated with SecinH3 for 3 hours or MAPK/NF-
B/transcription/translation inhibitors for 30 minutes followed by treatment with 10ng/ml IL-1. 
Alternatively, cells were infected with Ad-GFP or Ad-ARF6 (Q67L) adenovirus for 48 hours. 
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siRNA knockdown was performed as described and cells were treated with IL-1 72 hours after 
the second siRNA transfection.  Two hours later, horseradish peroxidase (HRP) was added to the 
top chamber at a final concentration of 100µg/ml. Medium was removed after 60 minutes from 
the lower chamber.  For time-course transwell assays and transcription/translation inhibitor 
experiments (Figure 1a, d), HRP was added to the insert at the same time as IL-1.  Transwell 
inserts were moved to fresh wells after each timepoint, and the concentration of HRP in the 
bottom chamber was measured for monolayer permeability. HRP was assessed using media 
samples obtained from the lower chamber incubated with 0.5 mM of guaiacol and 0.6 mM H2O2.  
Spectrophotometric analysis of absorbance at 490 nm provided a quantitative evaluation of the 
amount of HRP that crossed the membrane. Data are presented as mean ± SEM of at least three 
independent experiments performed in quadruplicate. 
Fluorescence-Activated Cell Sorting (FACS) 
FACS was performed as decribed31.  HMVEC-D were pre-treated with SecinH3 for 3 hours and 
then stimulated with 10 ng/ml IL-1 for 4 hours.  Analysis of the cell surface localization of 
adhesion molecules was performed with one step immunofluorescence staining using anti-hE-
selectin-FITC, anti-hICAM1-FITC and anti-hVCAM1-PE antibody (BD).  Data are presented as 
mean ± SEM of at least three independent experiments. 
Leukocyte Rolling and Adherence assay 
3 x 104 HMVEC-D were seeded into each well of a fibronectin-coated parallel plate flow 
chamber (U-plate 0.4 VI Fibronectin, Ibidi GMBH).  Media was changed daily using gentle 
aspiration until the cells had grown to confluence (approximately 3-5 days).  Human 
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described protocols32,33.  Briefly, human peripheral venous blood (500 mL) from healthy, 
medication-free, fasting adult subjects was drawn into acid-citrate-dextrose (1.4 mL ACD/8.6 
mL blood) through standard venipuncture technique and used immediately upon collection.  The 
University of Utah Institutional Review Board approved this study and all subjects provided 
informed consent.  Blood was centrifuged at 150 x g for 20 minutes at 20oC to separate platelet-
rich plasma (PRP) from red and white blood cells (RBC/WBC).  The PRP was removed and the 
remaining RBC/WBC mixture was resuspended in 0.9% sterile saline back to the original 
volume.  A volume equaled to half the original blood volume of 6% Dextran 70 (Sigma-Aldrich, 
St. Louis, MO) was then added to the RBC/WBC mixture and left for one hour. The leukocyte-
rich supernatant was removed and centrifuged at 400 x g for five minutes a 4oC.  The supernatant 
was then removed and the pellet resuspended (in 0.2% NaCl followed by an equal part of 1.6% 
NaCl), and the cells were centrifuged at 400 x g for five minutes at 4oC.  After centrifugation, the 
cells were resuspended in Hank’s Balance Salt Solution (Sigma-Aldrich, St. Louis, MO) with 1% 
human serum albumin (HBSS/A) (University of Utah Hospital, Salt Lake City, UT) and layered 
over an equal volume of Ficoll-Paque Plus (GE Healthcare Biosciences, Piscataway, NJ).  The 
layered cells were then centrifuged for 30 minutes at 400 x g at 4oC.  After 30 minutes, the 
mononuclear leukocyte layer was removed, followed by the RBC layer, HBSS/A layer, and 
Ficoll-Paque layer.  The remaining pellet containing greater than 95% PMNs was washed with 
HBSS/A and resuspended to 1 x 106 ml-1 in warmed ultrasaline (Lonza).  Endothelial cells in 
parallel-plate flow chambers were pretreated with IL-1 (10 ng/mL) and/or SecinH3 for 3 hours.  
A syringe pump (Harvard Apparatus) was used to flow the PMN solution through the parallel 
plate flow chambers at 1 dynes x cm-1 (a typical venous shear stress).  Differential Interference 
contrast microscopy (DIC) images were taken once per second using an Olympus inverted 
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microscope, and the total number of PMNs rolling and adhered in a 5 minute period were 
quantified using MetaMorph (Olympus) software.  The data is presented as fold over IL-1 
induced leukocyte rolling ± SEM and represents three independent experiments, each consisting 
of at least 3 replicates for each condition.   
Internalization assay 
VE-cadherin internalization assay was performed as previously described9.  Briefly, HUVEC 
were transfected with siRNA as described above and seeded onto 8-well chambered coverglass 
at 5 x 104;=DDK;GN=J?D9KK>L=J@GMJK
L@=;MDLMJ=O9K;@ADD=<9LX>GJEAFML=K

surface-labeled for 60 minutes on ice with 1 ug/mL dialyzed anti-VE Cadherin antibody (clone 
BV6, Millipore) in ice-cold labeling buffer (3% BSA in MCDB131 medium, Invitrogen).  At the 
end of 60 minutes, the labeling buffer was removed and the cells were treated with 0.6 mM 
Primaquine plus vehicle or 10 ng/mL IL-1, DMSO vehicle or 30 M SecinH3 or 50 M SC-
>GJEAFML=K9LX9F<*(GFGD9Q=JKO=J=O9K@=<LAE=s over 10 minutes 
with ice-cold HBSS (HBSS - Hank's Balanced Salt Solution, Invitrogen) + 50mM Glycine + 3% 
BSA, pH 2.7 to remove surface VE-cadherin.  One well for each condition was washed in a 
neutral pH solution to retain surface VE-cadherin staining.  Subsequently, monolayers were fixed 
immediately in 3% paraformaldehyde for 10 minutes.  The VE-cadherin antibody was detected 
using an Alexa-Fluor 488 conjugated anti-Mouse IgG antibody and traditional 
immunofluorescence methods.  To image the monolayers, five images per well were randomly 
selected using the DAPI channel at 600x.  Z-series images were taken using a confocal Olympus 
FV1000IX81 microscope.  Each treatment was done in triplicate.  The assay score represents the 
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Collagen-induced arthritis 
Collagen-induced arthritis (CIA) studies were conducted by Washington Biotechnology using 
their standard procedures and DBA/1J mice as previously published34-38.  All protocols were 
approved by their IACUC (Institutional Animal Care and Use Committee) prior to initiation of 
the study.  Six to seven week old male DBA/1 mice were used (Jackson Laboratories) with 5-20 
animals per group. Bovine type-II collagen (Chondrex) was dissolved in 0.01 M acetic acid, and 
an emulsion with 50 µl of Complete Freund’s Adjuvant was injected at the base of the tail at Day 
0.  21 days following the first injection, a booster injection consisting of a 50 µL emulsion of 
collagen in Incomplete Freund’s Adjuvant was injected at the base of the tail.  Arthritic index 
(AI) was scored for each limb of an animal as follows:  0 = no visible effects of arthritis, 1 = 
edema and erythema of one digit or joint, 2 = edema and erythema of two joints, 3 = edema and 
erythema of more than 2 joints, 4 = severe arthritis of the entire paw and digits accompanied by 
deformity of the limb.  The score for each limb was summed, with 16 as the highest possible AI 
score for each animal.  Treatments were either vehicle (0.5% DMSO/saline IP BID), SecinH3 
(0.1 mg/kg IP BID), or the positive control, Enbrel® (10 mg/kg SC OD).  The experiment was 
repeated multiple times with different endpoints; detailed descriptions of the exact timing for 
each experiment follow.  In all cases, treatment was initiated after mild arthritis was established 
(therapeutic treatment).  
EVAN’s BLUE DYE EXTRAVASATION:  Treatment was initiated when the average arthritic 
index for each group was between 3.4 - 3.55 and all mice in each group demonstrated a positive 
arthritic index.  Due to the variation in when each group reached an average arthritic index of 3.4 
– 3.55, treatment initiation day varied from study day 28 (seven days after the second collagen 
injection) to study day 30 (nine days after the second collagen injection).  The treatments lasted 
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for seven days until the mice were sacrificed for the Evan’s Blue Dye Assay (described in detail 
in subsequent methods). 
ARTHRITIS PROGRESSION:  Treatment was initiated when the average arthritic index for 
each group was 3.1 and all mice in each group demonstrated a positive arthritic index. Due to the 
variation in when each group reached an average arthritic index of 3.1, treatment initiation day 
varied from study day 28 (seven days after the second collagen injection) to study day 29 (eight 
days after the second collagen injection).  The treatments lasted for 13 days in all groups with 
arthritic index recorded regularly throughout. 
HISTOPATHOLOGIC PATTERNS:  Treatment was initiated when the average arthritic index 
for each group was between 3.1-3.2 and all mice in each group demonstrated a positive arthritic 
index.  Due to the variation in when each group reached an average arthritic index of 3.1 - 3.2, 
treatment initiation day varied from study day 29 (eight days after the second collagen injection) 
to study day 33 (12 days after the second collagen injection).  The treatments lasted for 14 days 
in all groups before joints were harvested for histology.  Limbs were preserved in 10% neutral 
buffered formalin for histology.  Limbs were decalcified in formic acid for 2-3 days, paraffin 
embedded, and 8 µm sections stained with toluidine blue.  Arthritis severity was evaluated for 
inflammation, pannus, cartilage damage, and bone damage.  
CYTOKINE EVALUATION:  Treatment was initiated when the average arthritic index for each 
group was 3.4 and all mice in each group demonstrated a positive arthritic index.  All groups 
reached an average arthritic index of 3.4 on day 34 (13 days after the second collagen injection), 
and treatment was initiated.  The treatments lasted for 1 day, at which time plasma and ankle 
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All selection and later scoring were blinded to treatment.  Data are represented as mean ± SEM. 
CIA - Cytokine or chemokine array 
CIA was induced as described.  24 hours after treatment of SecinH3, joints of mice were 
collected and pulverized using a mortar and pestle filled with liquid nitrogen. Tissue was 
transferred to 15 ml tubes, resuspended in 1 ml PBS and homogenized using a Polytron tissue 
homogenizer (PRO Scientific Inc. USA) for 20 s. Mouse joint homogenates were centrifuged for 
10 minutes at 500 g at 4°C. Supernatants were transferred to 1.5 ml Eppendorf tubes, centrifuged 
at 15,000 g for 5 minutes and collected for cytokine analysis by Quansys Biosciences. Data are 
presented as mean ± SEM for 6 mice per condition.  
CIA – Evans Blue permeability 
CIA was induced as described.  Seven days after randomization and treatment initiation, mice 
were given an IV injection of 5 ml/kg of 1% Evans Blue dye.  One hour later, mice were bled 
and plasma collected.  Mice were perfused, the hind limbs degloved, and ankle joints 
homogenized in 0.5 ml saline.  1.5 ml formamide was added and Evans Blue dye eluted 
overnight at 60°C.  Supernatant and plasma samples were read spectrophotometrically and 
expressed as OD620-OD740 joints divided by OD620-OD740 plasma.  Values were normalized 
to non-CIA-induced mice and expressed as fold increase over control.  N=14 per group and data 
are represented as mean ± SEM. 
Air-Pouch Model 
The Carrageenan-induced Air Pouch Model was performed by Washington Biotechnology as 
previously described39-41.    All protocols were approved by their IACUC (Institutional Animal 
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Care and Use Committee) prior to initiation of the study.  Six to seven week old male Swiss-
Webster mice were used (Harlan) with 6-8 animals per group.  On day 0, the nape of the neck 
was shaved and six mL of sterile air was injected subcutaneously.  On day 3, three mL of sterile 
air was injected subcutaneously.  On days 4 and 5, mice that were to be induced at a later time 
were injected with either 0.1 mg/kg SecinH3 IP BID, vehicle IP BID, or 10 mg/kg Enbrel® SQ 
QD.  On day 6 an additional injection was administered one hour prior to carrageenan 
injection.  One mL of 3% carrageenan (FLUKA) previously prepared in de-ionized water with 
heat, or 1mL of saline for the sham group, was then injected into the air pouch.  Four hours after 
carrageenan injection, the mice were anesthetized and 3mL of 10 U/mL heparinized saline was 
injected into the air pouch.  The air pouch was gently massaged, the contents immediately 
removed, and the exudate volumes recorded.  An aliquot of the exudate was transferred to 
heparin-treated microtainer tubes for differential white blood cell counting.  Samples with 
bloody exudates were discarded from white blood cell counting. 
Statistical analysis  
For the majority of data, one-way ANOVA (analysis of variance) with Tukey’s post-hoc test was 
used to assess statistical significance.  A Student’s t-test was used when the experiment was only 
composed of two groups. Two-way ANOVA with Bonferroni post-hoc test was used to assess 
statistical significance for data shown in Figure 4b. A P-value of less than 0.05 was considered 
statistically significant.  Unless otherwise noted, P-values of less than 0.05 are denoted with a 
single symbol (ie. *); P-values less than 0.01 are denoted with two symbols (ie **); P-values less 
than 0.001 are denoted with three symbols (ie ***); P-values less than 0.0001 are denoted with 
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CHAPTER 4  
 
TARGETING VEGFR ENDOCYTOSIS TO TREAT DIABETIC RETINOPATHY 
 
Abstract 
Vascular Endothelial Growth Factor (VEGF) is important for endothelial cell 
proliferation and migration and signals through cognate cell surface receptor tyrosine 
kinases (VEGFRs).  VEGF-induced VEGFR internalization is essential for signal 
amplification, yet the mechanisms coordinating the trafficking and intracellular signaling 
of VEGFR remain unknown.  We show VEGF signals to VEGFR to activate ADP-
Ribosylation Factor 6 (ARF6). ARF6 promotes binding of VEGFR to its co-receptor, 
neuropilin, internalization of the receptor, and amplification of receptor tyrosine kinase 
(RTK) signaling cascades.  We demonstrate that endothelial specific knockout of ARF6 
as well as small molecule inhibition of ARF6 dampens signaling to multiple downstream 
cascades including MARCKS and ERK, and mutes pathologic endothelial 
hyperpermeability in mouse models of diabetic retinopathy. This work demonstrates a 
VEGFR-neuropilin-ARF6 pathway controls VEGFR internalization and signaling and 






Vascular Endothelial Growth Factor (VEGF) is essential to the genesis and 
maintenance of the vascular endothelium1.  VEGF binding to its most recognized 
receptor, Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), promotes 
endothelial cell growth and migration, driving vessel development2.  VEGFR2 is a 
receptor tyrosine kinase (RTK) that upon ligand binding, dimerizes, trans-phosphorylates 
multiple intracellular residues3, and triggers downstream pathways including PKC-
MARCKS and RAF1-MEK1-ERK2,4-6.  RTK signal amplification depends on receptor 
internalization and intracellular trafficking7, highlighted by recent studies on the 
interaction between VEGFR2 and co-receptors including Neuropilin 1 (NRP1)8-10.  
Notably, loss of the cytoplasmic domain of NRP1 impairs VEGFR2 phosphorylation, and 
VEGFR2/NRP1 complexes formed in trans inhibit VEGFR2 internalization11,12.  How 
VEGFR2 activation controls its own internalization, and thus signal amplification, is not 
understood. 
We and others have shown that proangiogenic signaling through VEGFR2 
depends upon the activity of the small GTPase, ARF613,14.  ARF6, like RAB and other 
members of the RAS superfamily, modulates the trafficking of proteins from the plasma 
membrane and within intracellular compartments15,16.  Previous work from our laboratory 
defined a role for ARF6 in trafficking of cadherins and catenins to and from the cell 
surface17,18 and led us to ask what role(s), if any, ARF6 plays in VEGFR2-coreceptor 
internalization and signal amplification. 
RTK autoregulation of trafficking is of enormous interest to biology and 
medicine19.  The pharmaceuticals, erlotinib and lapatinib, inhibit epidermal growth factor 
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receptors and are prescribed to treat breast cancer; bevacizumab and sunitinib, used to 
treat colon cancer, inhibit VEGF-mediated signaling20,21.  The discovery that VEGF 
levels are elevated in vascular eye diseases informed the use of anti-VEGF agents to treat 
age-related macular degeneration and diabetic retinopathy.  These anti-VEGF drugs 
block ligand and receptor interactions at the cell surface (bevacizumab) or poison RTK 
activity (sunitinib)22.  Our elucidation of a pathway controlling VEGF receptor and co-
receptor internalization presents a new target to interfere with RTK signaling.  
 
Results 
Human retinal microvascular endothelial cells (HRECs) grown in vitro respond to 
VEGF stimulation with phosphorylation of VEGFR2 and a two-fold increase in activated 
ARF6, ARF6-GTP (Fig. 4.1A, quantified in Fig. 4.S1A), as well as an increase in cell 
migration (a surrogate measure of angiogenesis).  This migratory response can be 
inhibited by siRNA-mediated suppression of ARF6 expression (Fig. 4.1B and Fig. 
4.S1B).  ARF6 knockdown also reduces the phosphorylation of VEGFR2, MARCKS, 
and ERK (Fig. 4.1C, quantified in Fig. 4.S1, C to E).  MARKS and ERK are important 
components of two divergent arms of VEGF signaling and the ability of ARF6 
knockdown to affect these 2 pathways places ARF6 proximal to both.   
Early steps in VEGF signaling include internalization of VEGFR2 and binding of 
VEGFR2 to co-receptors.  The reduction of VEGF-induced VEGFR2, ERK, and 
MARCKS activation seen by siRNA inhibition of ARF6 were mimicked by inhibition of 
clathrin-dependent endocytosis (Fig. 4.1D, quantified in Fig. 4.S1, F to H), leading us to 
hypothesize that ARF6 is necessary for VEGFR2 internalization. Indeed, knockdown of 
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ARF6 in HRECs inhibited VEGF-induced VEGFR2 internalization (Fig. 4.1E).  
The activation of small GTPases such as ARF6 relies upon guanine-nucleotide 
exchange factors (GEFs).  One such GEF, GEP100, is known to be involved in RTK 
signaling and has been shown to bind to VEGFR213.  To probe its role in VEGF signaling 
we used siRNA to knockdown GEP100 in HRECs.  Such treatment predictably decreased 
VEGF-induced ARF6 activation and HREC migration (Fig. 4.1, F and G, quantified in 
Fig. 4.S2, A and B), but also inhibited VEGFR2 internalization, as well as VEGFR2, 
ERK and MARCKS phosphorylation (Fig. 4.1, H and I, quantified in Fig. 4.S2, C to E).   
Surprisingly we found that VEGFR2 co-immunoprecipitated with GEP100, 
independent of ligand binding (Fig. 4.1J).  To determine the GEP100 domain required for 
binding to VEGFR2, individual domains to VEGFR2 was assessed by co-
immunoprecipitation.  The Pleckstrin Homology (PH) domain was found to be necessary 
for binding (Fig. 4.S2, F and G).  Overexpression of this domain outcompeted 
endogenous GEP100 and blunted ARF6 activation, VEGF-induced VEGFR2 
phosphorylation, ERK activation, and MARCKS activation in HRECs (Fig. 4.1, K and L, 
quantified in Fig. 4.S2, H to K).  Together, these data identify the PH domain of GEP100 
as a critical mediator of ARF6-induced VEGFR2 internalization and subsequent 
signaling. 
Receptor trafficking is often enhanced through the interaction of receptors with 
co-receptors, and VEGFR2 has been demonstrated to utilize NRP1 in this fashion8,10,12,23.  
Knockdown of NRP1 in HRECs inhibited VEGF-stimulated migration, VEGFR2 
phosphorylation, ERK activation, MARCKS activation, and VEGFR2 internalization 
(Fig. 4.2, A to C, quantified in Fig. 4.S3, A to D).  Moreover, VEGFR2 was co-
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immunoprecipitated with NRP1, an interaction that was inhibited by the knockdown of 
ARF6 (Fig. 4.2D, quantified in Fig. 4.S3E).  These results show that NRP1 association 
and VEGFR2 internalization is dependent on ARF6 activation.  
Excessive VEGF signaling drives aberrant angiogenesis and pathological vascular 
leak in eye diseases such as age-related macular degeneration and diabetic retinopathy24. 
To determine if ARF6 plays a role in these pathways in vivo, we examined the 
consequences of pathologic VEGF signaling in mice lacking Arf6.  We first repeated the 
report that mice homozygous for a null-allele in Arf6 (Arf6 -/-) died in utero (26), 
reaffirming that Arf6 is essential to embryonic viability.  We next created a conditional-
null (floxed) Arf6 allele (Arf6fl), allowing us to generate compound heterozygous mice 
(Arf6fl/-) carrying an endothelial specific cre driver (Tie2cre) (Fig. 4.S4A).  These mice 
had no detectable ARF6 in aortic endothelial cells, yet appeared normal by criteria of 
size, fertility and behavior, showed no indication of embryonic lethality, or aberrant 
vessel development, and their retinal vasculature appeared normal throughout life (Fig. 
4.S4B). ARF6fl/-;Tie2Cre and control mice were given intraocular injections of saline or 
VEGF, and Evans blue dye extravasation from retinal vessels was quantified. As 
predicted, ARF6 endothelial knockout mice were less susceptible to VEGF-induced 
retinal vasopermeability (Fig. 4.3A).  
To examine VEGF signaling in a disease state, we induced diabetic retinopathy in 
mice with streptozocin (STZ). Eyes from STZ-induced wildtype mice demonstrate an 
increase in GTP-bound ARF6 (Fig. 4.3B), corresponding to increased retinal 
permeability as assessed by Evans blue extravasation (Fig. 4.S4C). The collection and 
storage process of human samples does not permit detection of ARF6-GTP, but we were 
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able to assess total ARF6 protein levels in human tissue.  Eyes from chronic diabetic 
patients showed higher levels of ARF6 than eyes from nondiabetic patients (Fig. 4.3C).   
Together, these mouse and human data led us to the hypothesis that inhibition of 
ARF6 may provide an effective pharmacologic target for treating VEGF-mediated 
vascular diseases. To test this hypothesis we induced diabetes in our endothelial specific 
ARF6 knockouts. Mice showing glucose levels above 300 mg/dL were assessed for 
Evans blue dye extravasation, and as we predicted, endothelial ARF6 knockout mice 
were less susceptible to diabetic edema (Fig. 4.3D).  
To further probe if inhibition of ARF6 activation is an effective treatment strategy 
for VEGF-mediated diseases, we made use of a chemically tractable, direct, reversible, 
and allosteric inhibitor of ARF6, NAV-2729 (Fig. 4.S4D). Treatment of cultured HRECs 
with NAV-2729 resulted in a reduction in the intracellular levels of the active, GTP-
bound form of ARF6 (Fig. 4.3E), blocked VEGF-induced VEGFR2 auto phosphorylation 
(Fig. 4.3F), and inhibited VEGF-induced migration of HRECs (Fig. 4.3G).  
To test the utility of using NAV-2729 to inhibit VEGF-induced retinal 
hyperpermeability in vivo, we first gave intraocular injections of saline+DMSO or 
VEGF+DMSO and measured Evans blue dye extravasation from retinal vessels.  VEGF 
treatment caused a 3-fold increase in dye extravasation that was completely abolished by 
the clinically used VEGF-inhibitor, Avastin. NAV-2729 similarly reduced VEGF-
induced permeability, while the negative control, DMSO did not (Fig. 4.3H).  These data 
strongly suggest that NAV-2729 is an effective inhibitor of VEGF signaling in vivo. 
To examine VEGF signaling in a disease state, we again induced diabetic 
retinopathy with STZ. Diabetic mice were treated with intraocular injections of DMSO, 
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NAV-2729, or SU4312 (a receptor tyrosine kinase inhibitor).  Mice treated with DMSO 
demonstrated vessel hyperpermeability, and this response was blunted in animals treated 
with SU4312 or NAV-2729 (Fig. 4.3I).   
 
Discussion 
The internalization and subsequent trafficking of cell-surface receptors is well 
documented as a modulator of signal transduction.  Although first characterized as a 
means of signal attenuation, current research, focused especially on the VEGFR, has 
shown the importance of receptor endocytosis in signal amplification25,26.   In this 
manuscript we have identified a key mediator of this process, the small GTPase, ARF6.  
Using biochemical and cell biological assays, small molecule inhibition, and mouse 
genetics, we have demonstrated that VEGF activates VEGFR internalization and 
signaling via a VEGFR-neuropilin-GEP-100-ARF6 protein interaction cascade. Our 
study showing the efficacy of targeting this cascade in an animal model of diabetic 
retinopathy not only provides support for this signaling model, but also identifies a 
potential therapeutic strategy for blunting RTK signaling in disease.  
Though this study is framed around VEGFR and the treatment of diabetic 
retinopathy, it should be viewed in a wider context. Other members of the RAS 
superfamily linked to pathways in which receptor internalization is important for signal 
amplification deserve investigation, as do other diseases where inhibition of RTK has 
been shown to have therapeutic promise. The use of retinal endothelial cells was 
fundamental for studying VEGF signaling in retinal vascular disease, but this new 
pathway needs to be explored in the context of other cell types 20,21. Perhaps this 
 84 
discrepancy in cell type is why we did not find ERK phosphorylation to be independent 
of ARF6 as previously reported 13,27.  
The genetic and small molecule probes we have generated can be similarly used 
to interrogate other signaling pathways characterized by receptor internalization. Should 
Arf6 be involved in EGF signaling, for example, these tools could help resolve the 
controversy over whether EGFR internalization results in signal amplification or receptor 
down regulation25,28-30.  Furthermore, given the benefits of RTK-inhibition in cancer 
therapy, the relevance of our model in oncogenesis should also be probed. The tools 
described here--a tissue-specific null allele of Arf6 and a high-affinity reversible inhibitor 
of ARF-- will be critical for these future studies. In addition, though we believe our 
chemical probe, NAV-2729, targets endothelial ARF6, as demonstrated by similar 
reductions in STZ-induced retinal vasopermeability using compounds and using 
conditional knockout mice, NAV-2729 may also target other cells and other pathways. 
Further investigation into the global role of ARF6 is thus needed especially using genetic 
ablation postembryonically.  
The identification of ARF6 and its role in early stages of intracellular signaling 
unites our understanding of the inherent role of ARF6 in intracellular trafficking with the 
discovery that receptor endocytosis is essential for signal amplification. Though further 
work is required to advance our understanding of both receptor-mediated endocytosis and 
ARF6 itself, we demonstrate a pathway and a therapeutic strategy for inhibiting RTK 




Materials and Methods 
Reagents: Human Retinal Endothelial Cells (HRECs) at passage 0 from Cell 
Systems were cultured with EGM-2 MV (Endothelial Cell Basal medium-2 supplied with 
EGM®-2 MV SingleQuotes®, Lonza). Rabbit anti-p-ERK1/2 antibody, rabbit anti-
VEGFR2 antibody, rabbit anti-VEGFR2 pY1175, rabbit anti-pMARCKS, rabbit anti-
Caveolin, rabbit anti-Clathrin rabbit anti-MARCKS, rabbit anti-VEGFR 2 antibody 
(Sepharose Bead® Conjugate), and mouse anti-ERK were from Cell Signaling. Mouse 
anti-ARF6 antibody was from Millipore or Cell Biolabs, mouse anti-VEGFR2 was from 
R&D, goat anti-NRP1 antibody was from Santa Cruz, and rabbit anti-GEP100 antibodies 
were from Sigma. siRNA were from Qiagen. ARF6-GTP pull-down kits were from 
Thermo Scientific, VEGF-165 were from R&D, and the ChemoTx system for monitoring 
cell migration were from Neuroprobe. Standard molecular biology and cell culture 
reagents were primarily from Life Technologies and NAV-2729 was from Navigen LLC. 
Human Samples: Human donor eyes were purchased from the Lions Eye Bank at 
the University of Utah. Tissue from 10 different donors was analyzed. The donor ages 
varied between 52 and 84. The interval between death and tissue processing varied 
between 6 and 12 hours. The records received from the eye bank stated the donor eyes as 
diabetic and nondiabetic. The western analysis is exempt of IRB approval. 
Transfection and siRNAs: siRNAs were diluted in 12.5% HiPerFect Transfection 
Reagent (Qiagen) in Optimem (Invitrogen) and incubated 10-20 minutes at room 
temperature. Passage 3-4 HREC cells were resuspended in EGM2-MV and combined 
with siRNAs such that the final concentration of siRNA was 30 nM (all targets). The 
cells were plated, allowed to grow overnight, and then the growth media was replaced. 
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Three days after the initial transfection, the cells were transfected a second time using the 
same HiPerFect/siRNA concentrations as above. 
The following is a list of all siRNAs used, their catalogue numbers and sequences: 
Allstars Negative Control siRNA, SI02757286 (CAACGTGGAGACGGTGACTTA), 
SI03019408 (CTGAAGGGTAGCAGTAATGAA), SI00057114 (CAGATTATCCTTG-
CTCTGGAA). All siRNAs were purchased from Qiagen. We have used most of these 
previously in another publication18. The average knockdown was observed by western 
blot and quantified in Supplementary Figures 4.1 and 4.2. 
Protein Expression Constructs: The coding sequences of each functional domain 
or full-length GEP100 (BC010267) were amplified from an IMAGE cDNA clone by 
PCR. The PCR products were ligated into pcDNA3.1 vector after Acc65I and NotI 
enzyme digestion. Constructs were confirmed by DNA sequencing. All constructs were 
fused at the C-terminus with the HA epitope. 
ARF6-GTP Pull-Down Assay: ARF6-GTP pull-down assays were performed as 
described18. Briefly, HREC cells were untreated or transfected with siRNA as described 
above. Cells were treated with VEGF (20ng/ml) for 5-minutes 72 hours after the second 
siRNA transfection for 5 minutes. For assessing the effects of small molecule compounds 
on the intracellular levels of active ARF6, HRECs were grown on EGM2-MV medium in 
6-well tissue culture plates to 80-90% confluency and exposed to test compounds (25µM) 
in basal EBM-2 medium supplemented with 1% FBS for 3.5 hours. After treatment, 
media was aspirated and cells were rinsed with chilled Ultrasaline (Lonza). Dishes were 
frozen on dry ice. Following thawing, ARF6 pull-down lysis buffer [Tris-HCL] 50mM, 
NaCl 100mM, MgCl2 1mM, NP-40 1% glycerol 10% protease inhibitors (Roche) and 
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phosphatase inhibitors (Sigma)] was added to cells. Lysates were centrifuged and 
supernatants were added to GGA3-conjugated beads (Cell Biolabs, sta-40706), and 
agitated at 4°C for 60 minutes. Beads were washed in ARF6 pull-down lysis buffer and 
resuspended in 2X Laemmli buffer prior to loading on 15% SDS-PAGE gels. A fraction 
of the cell lysate was withheld for use as a measure of total ARF6 in each sample.  
Migration Assay: HREC cells were grown under standard conditions with EGM-2 
MV and incubated in EBM-2 with 0.1% fatty acid-free BSA (Equitech-Bio, Inc) 
overnight. Cells were then harvested with Trypsin/EDTA (PromoCell) and resuspended 
at 0.6 x 105 cells / ml. 20ng/ml VEGF was placed in the lower wells of a 48-well 
chemotaxis chamber (Neuroprobe). A fibronectin-coated (overnight at 4°C) 
polycarbonate membrane (10 mm; Neuroprobe) was placed between the chemo attractant 
and the cells. HREC cells (50 µl, 30,000 cells) were added to the upper wells. After 
incubating at 37°C for 2 hours, cells on the top surface of the filter were removed with q-
tips and cells that had migrated through the filter onto the undersurface were fixed and 
stained using Diff-Quik stain set (Dade Behring). Migrated cells in five high-power fields 
were counted and migration was expressed as the percent of cells migrated relative to 
cells migrated toward EBM-2 media containing 0.1% fatty acid-free BSA and no VEGF. 
Data are presented as s.e.m. of at least three independent experiments. 
Chemotactic Cell Migration Assay: Pharmacologic effects on VEGF-induced 
motile activity of HRECs was assessed using 96-well-based ChemoTx system 
(NeuroProbe) designed for monitoring migration of cells across a polycarbonate 
membrane along a gradient of chemoattractant31 The basal medium EBM-2 used for this 
test was supplemented with ascorbic acid (1 µg/ml) and hydrocortisone (0.2 µg/ml). Both 
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polycarbonate membrane filters (pore size of 8 µm) and wells of the bottom (cell 
collector) plates were precoated with fibronectin. The 45-µl aliquots of a suspension of 
serum-starved cells in EBM-2 containing 0.1% BSA (8x105 cells per ml) were pipetted 
on the top of the membrane filter, which was assembled on the top of collector plate. The 
wells of the latter were filled with EBM-2 supplemented with 0.9% FBS (30 µl per well). 
Each test compound at a desired concentration or DMSO control was added to the 
matched samples on top of the membrane and in the bottom plate. Each fully assembled 
ChemoTx system was incubated in a tissue culture incubator overnight followed by 
aspiration of media from top of the membrane, cell staining on both sides of the 
membrane using CyQUANT dye (Life Technologies), and removal of nonmigrated cells 
from the top of the membrane by wiping and rinsing. Finally, the stained migrated cells 
were quantified fluorometrically using a Synergy 4 plate reader with the excitation and 
emission wavelength settings of 485 nm and 528 nm, respectively.        
Internalization Assay: VEGFR2 internalization assay was performed as 
previously described18,32,33. Briefly, HRECs were transfected with siRNA as described 
above and seeded onto 8-well chambered coverglass at 3 x 104cells/coverglass. The cells 
were immediately re-transfected with siRNA for 24 hours. Before assaying, the cells 
were serum-starved for 4 hours in EBM-2 + 0.1%fatty acid-free BSA (Equitech) and 
blocked in 2% FAF BSA+4% normal donkey serum, prepared in Assay Buffer (EBM-
2+0.25mM HEPES, pH7.8) for 10 minutes. Purified VEGFR2 antibodies were then fed at 
8µg/ml in warmed Assay Buffer for 20 minutes. The monolayers were washed twice in 
warmed HBSS+Ca+Mg and then stimulated in Assay Buffer with 20ng/ml VEGF165 for 
1 minute at 37˚C and 5% CO2 in the presence of 0.6mM Primaquine (Sigma). 
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Monolayers were then washed 3 times over 7 minutes with ice-cold Hank's Balanced Salt 
Solution (HBSS, Invitrogen) + 50mM Glycine + 3% BSA, pH 2.7 to remove surface 
VEGFR2. Monolayers were subsequently fixed in 4% paraformaldehyde for 10 minutes. 
VEGFR2 was detected using 10 µg/ml Donkey anti-mouse IgG Alexa 488 (VEGFR2) 
applied for 1 hour at room temperature. Wells were washed 3x in HBSS+Ca+Mg, and 
mounted in 1 µg/ml DAPI in Glycerol + 0. 25µg DABCO, 0.02% sodium azide. 15 Z-
stacked images were collected per condition (5 images/well x 2 wells/treatement) at 
1200x oil immersion on an Olympus FV1000 confocal laser microscope. VEGFR2 
internalization was scored by taking the percentage of VEGFR2 vesicle-positive cells 
present per frame of cells imaged. Internalization was specifically defined by the 
presence of 10 or more Alexa 488-labeled vesicles per cell. 
Immunoprecipitation: Immunoprecipitation assays were performed as described33. 
Briefly, HREC cells were treated with 20ng/ml VEGF for 1 or 5 minutes. Cells were then 
washed with ice-cold PBS and lysed with ice-cold lysis buffer (Tris-HCL 50mM, NaCl 
250mM, NP-40 1%, glycerol 10% with protease and phosphatase inhibitors (Thermo 
Science). Cell lysates were centrifuged for 15 minutes at 13,000g and the supernatants 
saved. BCA assays (Pierce) were used to determine protein concentrations. Lysates were 
precleaned with protein A/G-Sepharose (Santa Cruz Biotechnology) for 2 hour at 4˚C. 
Precleaned lysates were incubated with 8 mg of the indicated antibody and protein A/G-
Sepharose (Santa Cruz Biotechnology) for 1 hour at 4˚C. Beads were then washed 5x in 
lysis buffer. The immunoprecipitates were assayed by western blot analysis using 
Peroxidase-conjugated AffiniPure Light Chain Specific secondary antibody for signal 
detection.  
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Animals: The Institutional Animal Care and Use Committee at the University of 
Utah approved the mouse studies (IACUC nos. 14-09002 and 11-12007). The Arf6 gene 
was mutated by homologous recombination in mouse embryo-derived stem(ES) cells.  
Two alleles were generated.  The conditional (fl) allele contains one loxP site 5’ of the 
Arf6 gene at position 69,371,642 (UCSC genome browser) on Chromosome 12, and a 
second loxP site 3’ of the Arf6 open reading frame at position 67,373,928.  The null (-) 
allele was generated by deleting the sequences between the two loxP sites by Cre-
mediated recombination using HPRTcre (Jackson). Endothelial specific knockout of 
ARF6 was achieved by crossing ARF6fl/fl mice with Tie2cre mice (Jackson).  
Retinal Permeability:  Retinal permeability was assessed as previously 
described34-36. In brief, 8-10-week-old mice were anesthetized with ketamine-xylazine 
(0.2 mg/g) and then given intraocular injections of 1µl of 50ng VEGF-165 (R&D 
Systems) with 50ng SU4312 or NAV-2729. An equivalent volume of VEGF in 100% 
DMSO was injected into the eyes of control animals. Half an hour later, 50µl of 60mg/ml 
Evans blue solution (Sigma) in Ultrasaline was administered into the tail vein. After 5 
hours, mice were killed and eyes were enucleated and retinas dissected. Dye was eluted 
in 0.4 ml formamide for 18 h at 70 ̊C. The extract was centrifuged for 14,000rpm for 5 
min. Absorbance at 620 nm was measured. Background absorbance was measured at 740 
nm and subtracted out. Data are presented as mean ± s.e.m. of 2-4 mice per genotype. 
STZ-induced Diabetic Retinopathy.  Diabetic retinopathy was induced as previously 
described34. Briefly, for five consecutive days, 6-8 week old CD1 mice (Charles River) 
were fasted for 4 hours and then injected I.P. with either 75 mg/kg of streptazocin 
(Sigma-Aldrich) in sodium citrate buffer or sodium citrate buffer control. After 4 weeks, 
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tail-snip blood glucose was determined by glucometer (Aviva) to verify hyperglycemia 
(blood glucose concentrations greater than 300 mg/dL) in the STZ-treated animals. The 
animals were then divided into treatment groups such that body weight and blood glucose 
were distributed similarly among groups. Retinal permeability was assessed as explained 
above. 
Statistical Analysis: All quantifications for western blots are in the supplementary 
materials. For the majority of data, one-way ANOVA (analysis of variance) with Tukey’s 
post-hoc test was used to assess statistical significance. A Student’s t-test was used when 
the experiment was only composed of two groups. Welch’s ANOVA with Games-Howell 
multiple comparison test was used to assess statistical significance for data down in 
Figure 4.4B. A P-value of less than 0.05 was considered statistically significant. Unless 
otherwise noted, P-values of less than 0.05 are denoted with a single asterisk (i.e. *); P-
values less than 0.01 are denoted with two asterisks (i.e. **); P-values less than 0.001 are 
denoted with three asterisks (i.e. ***); P-values less than 0.0001 are denoted with four 
asterisks (i.e. ****). 
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Fig. 4.1. Immediate VEGF signaling is ARF6 dependent. (A) VEGF-treated HREC 
assayed for ARF6-GTP. (B to C), ARF6-siRNA-treated HRECs assayed for migration 
(B), and VEGFR2, ERK1/2, MARCKS phosphorylation (C). (D) Pitstop2™-treated 
HRECs assayed for VEGFR2, ERK1/2, and MARCKS phosphorylation. (E), 
Immunofluorescent localization of internalized VEGFR2 in ARF6-siRNA-treated 
HRECs. (F to I), GEP100-siRNA-treated HRECs assayed for ARF6-GTP levels (F), 
migration (G),  internalized VEGFR2 (H), and VEGFR2, ERK1/2, and MARCKS 
phosphorylation (I). (J) HREC cell lysates immunoprecipitated with anti-GEP100 and 
immunoblotted with anti-VEGFR2 and anti-GEP100. (K to L), HRECs transfected with 
GEP100 PH domain and assayed for ARF6-GTP levels (K), and VEGFR2, ERK1/2, and 
MARCKS phosphorylation (L). n≥3; error bars represent s.e.m. *P<0.05, **P<0.01, 
***P<0.0001. Quantifications of blots shown in panels A, C, D, F, G, I, J, K, and L are in 





























Fig. 4.2. VEGFR/NRP1 binding is ARF6 dependent and is necessary for internalization. 
(A to C) NRP1-siRNA-treated HRECs assayed for migration (A), VEGFR2, ERK1/2, 
and MARCKS phosphorylation (B), and internalized VEGFR2 (C). (D) VEGFR2 
precipitation and NRP1 immunoblotting with control or ARF6 siRNA. n≥3; error bars 
represent s.e.m. *P<0.05, **P<0.01, ***P<0.0001. Quantifications of blots shown in 








Fig. 4.3. Genetic and drug inhibition of ARF6 is protective against hyperpermability in 
diabetic retinopathy. (A) VEGF-induced retinal permeability in endothelial knockout 
mice compared to littermate controls. (B) Diabetic mouse eye lysates immunoblotted for 
ARF6 and ARF6-GTP. (C) Diabetic human eye lysates immunoblotted for ARF6. (D) 
STZ-induced diabetic permeability in endothelial knockout mice compared to littermate 
controls. (E to G) Effects of NAV-2729 on VEGF-induced ARF6-GTP levels in HRECs. 
(E), VEGFR2 phosphorylation (F), and migration of HRECs (G). (H) Intraocular VEGF-
induced retinal permeability as assessed by Evans blue dye extravasation in mice treated 
with DMSO, SU4312, or NAV-2729. (I) STZ-induced diabetic permeability in mice 
treated with DMSO, SU4312, or NAV-2729. n≥6 animals; error bars represent s.e.m. 
*P<0.05, **P<0.01, ***P<0.0001 relative to control. 
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Fig. 4.S1. Supporting data and quantification of immunoblots in Fig. 1, A to E. (A) 
Quantification of ARF6-GTP levels in HRECs treated with VEGF. (B) Cell lysates from 
HRECs transfected with control siRNA or ARF6 siRNA immunoblotted with anti-ARF6 
antibody to confirm knockdown. (C to E) Quantification of immunoblots represented in 




























Fig. 4.S2. Supporting data and quantification of immunoblots in Fig. 1, F to L. (A) 
Cell lysates from HRECs transfected with control siRNA or GEP100 siRNA 
immunoblotted with anti-GEP100 antibody to confirm knockdown. (B) Quantification of 
immunoblots represented in Fig. 1F. (C to E) Quantification of immunoblots represented 
in Fig. 1I. (F) Schematic representation of GEP100 (full) and serial fragment constructs 
(N, dN, Sec7+PH, Sec7, PH, PH+C, C) All GEP100 fragments represent HA fusion (HA-
tag) constructs containing the specified fragments of GEP100. (G) IP with anti-VEGFR2 
antibody and immunoblotting with anti-VEGFR2 and anti-HA antibodies in HEK293T 
cells ectopically expressing each serial fragment of GEP100. (H) Quantifications of 
immunoblots represented in Fig. 1K. (I to K). Quantifications of immunoblots 






Fig. 4.S3. Supporting data and quantification of immunoblots in Fig. 2. (A) Cell 
lysates from HRECs transfected with control siRNA or NRP1 siRNA immunoblotted 
with anti-NRP1 antibody to confirm knockdown. (B to E) Quantification of immunoblots 















Fig. 4.S4. Generation and validation of ARF6 endothelial knockout mice. (A) 
Schematic of ARF6 knockout mice. (B) Validation of ARF6 knockout from lysates of 
aortic endothelial cells. (C) Evans blue permeability in mice treated with Saline or STZ. 
(D) Structure of NAV-2729  
 
 




The findings presented in this dissertation add two major contributions. First is 
proof of principle that the proteasome is necessary for proplatelet formation. Loss or 
inhibition of the proteasome does not affect megakaryocyte maturation but does blunt 
platelet production to the extent that mice succumbed to multi-organ hemorrhage. 
Contrary to the prevailing hypothesis, the failure to form proplatelets under bortezomib 
treated conditions stems from over activation of RhoA signaling rather then an inhibition 
of NFκB1,2.  This alters and adds to our understanding of what drives the final stages of 
megakaryocyte maturation and the beginning of proplatelet formation.  
It is clear that platelets are important to the maintenance of the vascular 
endothelium and are crucial to inflammatory response3,4. However, it is not well 
understood how these platelets are formed. Though our findings solve the question of 
how one drug (bortezomib) causes thrombocytopenia, it leaves open the question of how 
megakaryocytes signal for their own morphogenesis into proplatelets and subsequently 
platelets5. By creating a mouse that has normal megakaryocyte maturation but impaired 
proplatelet formation (Psmc f/f; PF4cre), we have provided a useful tool for dissecting 
this latter question. To this extent, we have performed mass spectrometry using CLICK-
IT to track the proteins generated in the final hours of megakaryocyte maturation. 
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Comparing proteasome knockout megakaryoctyes with WT, we have generated a list of 
potential proteins that may influence this crucial process. It is in this manner that we hope 
to begin to piece together the signaling pathways that are involved in thrombocytopoiesis. 
The second contribution of this work is towards our understanding of signaling 
events downstream of proinflammatory and proangiogenic signals, specifically IL-1b and 
VEGF. Our work places the small GTPase, ARF6 as a rheostat in both signaling 
pathways, modulating endothelial cell permeability and signal amplification, 
respectively. Current medical therapies to prevent diseases of excessive cytokine 
signaling involve targeting one cytokine at a time. Though effective, this is often 
inefficient. Our increasing understanding of ARF6 as a modulator of multiple 
inflammatory signaling pathways may provide a unified way of muting all inflammatory 
pathways. 
Though we uncovered that ARF6 may be involved in VEGFR2 endocytosis and 
signal amplification, the exact mechanism still needs to be elucidated. It is unclear at 
which endosomal compartments signal amplifications occur and how ARF6 regulates the 
temporal and spatial relationships of VEGFR2, NRP1, and VE-Cadherin. Future work 
using specific inhibitors at different VEGFR2 phosphorylation sites in the presence and 
absence of ARF6 knockdown may solve some of these questions. In addition, staining for 
these membrane proteins in conjunction with Rab5, Rab7, and Rab 11 markers may also 
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